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Abstract 
 Recently we have demonstrated that several chemotherapy agents, of distinct 
mechanisms, promote highly reproducible ribosomal RNA (rRNA) degradation patterns, a 
phenomenon we call RNA disruption. These reproducible rRNA degradation bands have been 
observed in total RNA preparations from several cancer cell lines originating from various 
tissues. However, the effect of chemotherapeutic agents on ribosomal integrity and composition 
(including changes in rRNA and protein content) has not been examined. The purpose of the 
present study was to investigate the effect of docetaxel (DXL) chemotherapy treatment on 
ribosomal RNA and protein content in the A2780 ovarian carcinoma cell line. This involved 
isolation of ribosomes from untreated and DXL-treated A2780 cells using a differential 
centrifugation method. Differences in ribosomal RNA integrity and protein composition due to 
DXL treatment were determined using capillary gel electrophoresis (for rRNA), and 1D or 2D 
gel electrophoresis (for ribosomal proteins). Specific ribosomal proteins were detected by 
western blotting and quantified using densitometry. We report that DXL treatment of A2780 
cells results in time-dependent degradation of rRNAs within isolated ribosomes, as well as 
changes in their relative protein composition. The DXL-induced changes in ribosome protein 
composition appeared to precede extensive rRNA degradation and were not observed in DXL-
resistant A2780 cells. 
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1.0 Introduction 
1.1 Ovarian Cancer, Complications and Treatment 
     1.1.1 Statistics Including Typical Patient Outcomes 
Cancer poses one of the greatest threats to overall human health; it has now become the 
leading cause of death in Canada. In 2015, 196,900 new cases of cancer were diagnosed in 
Canada and 78,000 Canadians died of cancer
1
. This has driven a large increase in the efforts and 
funding being dedicated towards discovering cancer treatments, cures and improving care. With 
a total of 1 .6 million cancer cases (and just under 600 000 deaths) emerging per year in the 
United States, the U.S National Cancer Institute funding towards cancer research reached a total 
of 5 billion dollars
2
. Ovarian cancer is of great importance in the cancer research field because it 
is the most lethal gynecological cancer and the fifth leading cause of cancer death among women 
in the western world
3,4
. Worldwide, it is the eighth most common malignancy among women, 
resulting in more than 140 000 deaths
4
. The five year survival rate for advanced ovarian 
carcinoma is only 45%
2
. The high mortality rate can be attributed to the absence of symptoms 
early in the disease trajectory, resulting typically in a diagnosis of ovarian cancer at a very 
advanced stage
5
. The late diagnosis of ovarian cancer is one of the largest hurdles to overcome 
because there is a lack of effective screening procedures and early diagnosis methods
5
. 
Approximately 75% of patients with ovarian cancer present with tumour metastases, resulting in 
poor prognosis and high mortality
6
. The main reason that ovarian cancer progresses to such an 
advanced and lethal stage before detection is likely due to the fact that it is often isolated inside 
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the peritoneal cavity
7
. Additionally, early stage ovarian cancer may not cause many symptoms, 
or they may be vague and overlooked such as increasing pelvic pressure or pain, change in bowel 
habits such as diarrhea or constipation, or more frequent or urgent urination
8
. This also speaks to 
the lack of a sufficiently robust biomarker for early ovarian cancer detection
9
, although Ca125 
continues to be used in screening trials and for monitoring response to chemotherapy
9
. 
Another significant factor contributing to the lethality of ovarian cancer is drug 
resistance. This entails both the innate or primary resistance of the tumour to chemotherapy, 
along with acquired resistance after chemotherapeutic treatment
10
. Resistance frequently 
develops to all classes of drugs used in ovarian cancer
11
 and has been attributed to distinct 
biochemical pathways depending upon the agent used. Single and dual agent resistance is 
documented, with distinct mechanisms occurring for each drug in single agent treatment and also 
different mechanisms during dual agent resistance
12
. Mechanisms of resistance to chemotherapy 
treatment in ovarian cancer have been attributed to: relative dose intensity playing a role in 
resistance to platinum complexes, induction of the membrane P-glycoprotein conferring 
resistance to taxanes and activation of DNA repair mechanisms.  Avoiding drug-induced cell 
death mechanisms is also characteristic of resistance to platinating agents and to a lesser degree 
taxanes
13
.  
Ovarian cancers comprise a heterogeneous group of neoplastic diseases, with epithelial 
tumors as the most common ovarian cancer and also the most lethal gynecological malignancy. 
Based on histopathology and molecular genetic alterations, ovarian carcinomas are divided into 
five main subtypes [high-grade serous (70%), endometrioid (10%), clear-cell (10%), mucinous 
(3%), and low-grade serous carcinomas (<5%)]
14
. The most common subtype of ovarian cancer, 
high grade serous carcinoma (HGSC), which accounts for up to 80% of ovarian cancer related 
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deaths almost always carries TP53 mutations
14
. A pathogenic model for ovarian cancer described 
by Bowtell et al.
15
 proposes as primary events early p53 loss, followed by BRCA loss, leading to 
a deficiency in repair of double strand breaks (DSB) by homologous recombination.  This 
triggers chromosomal instability (genetic chaos) and widespread gene copy number changes
16
;  
events that cause global changes in gene expression which facilitate tumor evolution
16
.  
1.1.2 Surgery and Chemotherapy Agents Used in Adjuvant and Neoadjuvant Settings in 
Ovarian Cancer 
In North America, advanced stage ovarian tumours are most frequently treated by 
performing cytoreductive surgery initially, to remove the bulk of the mass of the tumor followed 
by adjuvant chemotherapy
17,18
. The current standard adjuvant regimen employs more than one 
cytotoxic chemotherapy agent, usually combining a platinating agent and a taxane
19
. The most 
common platinating agents encountered are cisplatin and carboplatin, with carboplatin 
demonstrating less nephrotoxicity and neurotoxicity,  making it the drug of choice
20
. For taxanes, 
paclitaxel and docetaxel (DXL) are the sole agents used. In recent years, there has been a higher 
usage of DXL due to reduced cost (the drug has become off patent) and considerably less 
neuropathy. The hematologic toxicity of DXL is greater
21
, although it can be relatively easily 
monitored and remediated by pegfilgrastim administration compared to the neuropathy induced 
by paclitaxel. This likely contributes to the popularity of DXL compared to paclitaxel. At 
present, adjuvant therapy is mainly dependent upon tumour stage and grade rather than type, 
although it is known that type I ovarian cancers (low grade serous cancer, clear cell, mucinous 
and endometrioid) do not respond well to current cytotoxic chemotherapy using platinating 
agents and taxanes
22
. This may change in the future with the development of new 
chemotherapeutic agents, targeted therapies and clinical trials
23
. Another aspect of treatment 
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under current debate is the efficacy of adjuvant versus neoadjuvant chemotherapy treatments in 
advanced stage ovarian HGSC
18,24
. In a small percentage of advanced stage tumours in North 
America, patients undergo neoadjuvant chemotherapy before de-bulking surgery. However, in 
Europe, neoadjuvant chemotherapy followed by interval de-bulking has shown promise, and is 
the standard of cancer care
17,25
. 
  Over the past decade or so, there has been some small improvement in prognosis for 
ovarian cancer. During this time, the combination of carboplatin and paclitaxel/DXL has 
remained the standard first-line therapy. Response rates to this combination are in the region of 
70%–80%, but the majority of these women subsequently relapse9. Despite a promising initial 
response to surgery and adjuvant chemotherapy, more than 50% of patients will fail to respond to 
chemotherapy and will develop a recurrent form of ovarian cancer, which is typically resistant to 
the previously administered chemotherapy agents
26
. This failure of the chemotherapeutic 
treatment in recurrent ovarian cancer is largely due to the evolution of resistance to the two 
classes of antineoplastic agents most commonly used to treat ovarian cancer: taxanes and 
platinating agents
27
. Resistance to both agents is not uncommon. Recent research into the 
resistance mechanisms of drug-resistant ovarian cancer has demonstrated that distinct gene 
expression changes take place as ovarian tumours or tumour cells acquire resistance to taxanes, 
carboplatin, or both drugs
12
. 
In some instances, particularly where primary de-bulking surgery is not suitable for 
ovarian cancer patients, neoadjuvant chemotherapy may be considered as a treatment option for 
patients suffering with advanced disease
28
. As well, in the case of recurrent disease for treatment 
of patients where surgery is not feasible or where platinum resistance is established, taxanes are 
the primary chemotherapeutic agent of choice
29
.  
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     1.1.3 Taxanes and Their Mechanism of Action 
Taxanes are one of the most efficient and frequently used chemotherapy agents, applied 
in the treatment of a wide range of tumors and cancer settings.  The first taxane to be isolated and 
purified for clinical usage was paclitaxel
29
. The two most commonly used taxanes encountered 
during ovarian cancer treatment are paclitaxel and DXL. Currently, in the clinic, taxanes are 
being used alone, following another drug regimen, or in combination with other drugs to treat 
several types of cancers
30
. DXL is active against several solid tumours including breast, gastric, 
ovarian and non-small cell lung cancer
31
. A recent ovarian cancer study showed that the addition 
of DXL (rather than paclitaxel) with the platinating agent resulted in an improved quality of life 
for the same length of progression free survival. This then identified DXL as an improved 
alternative for paclitaxel in ovarian cancer treatment
21,32
. Although other taxane derivatives exist, 
they are rarely used to treat cancer. 
 Paclitaxel is derived from the bark of the pacific yew tree (Taxus brevifolia), while DXL 
is a semi-synthetic derivative of the latter
31
. Both are known as mitotic inhibitors; they arrest the 
cell cycle of actively dividing cells 
33
. Specifically, taxanes are cytotoxic drugs (meaning toxic to 
cells) that interfere with microtubule depolymerisation, causing cell cycle arrest in mitosis and 
followed by cell death via apoptosis
34
. However, apoptotic cell death is not the only type of cell 
death reported to occur following taxane exposure in cancer cells. It is also reported that taxanes 
induce multinucleation of cells followed by death via mitotic catastrophe
35
.  
Microtubules are important in retaining cell shape, allowing movement of organelles and 
facilitating cell division. Taxanes exhibit unique cytotoxic activity by stabilizing microtubules 
rather than destabilizing them, as vinca alkaloids do
36
. In particular they promote the assembly of 
microtubules but prevent their depolymerization, thus interfering with a number of normal 
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cellular functions that depend on the physiological balance between tubulin and microtubules
37
.  
This includes the ability of taxanes to block a phenomenon called treadmilling (a well-known 
process by which tubulin dimers added on to the microtubules at their plus ends are released 
from the minus ends)
38
. Blockage of treadmilling inhibits further progression in cell division and, 
hence, cell cycle progression. When taxanes bind to microtubules, which are polymers composed 
of α and β-tubulin, they bind tightly to β-tubulin monomers in the microtubules36. 
 
Preliminary research indicates that mainly the intrinsic (Bcl-2 mediated) apoptotic 
pathway is activated as a result of taxane chemotherapy treatment; however there may be 
alternate pathways to promote apoptosis or other cell death pathways 
39
. Research reports that 
alternate apoptotic pathways, initiated through various distinct caspases are possible, and may be 
dependent on the cell type/line
40,41
. However, taxanes have also been shown to induce caspase-
independent cell death pathways, both in vitro and in vivo, depending upon the dose, tumour 
microenvironment and cell type
40
. Several studies have also shown the involvement of 
autophagic cell death in taxane treatment of several types of cancers
42
. Cytokine and interleukin 
production have been reported in response to DXL and their relationship to the mechanism of 
action of DXL is still unclear
43
. Of increasing interest lately, is the cell signaling molecule TNF-
α, or tumor necrosis factor alpha, involved in systemic inflammation and the initiation of 
apoptosis. A study investigating treatment of breast and ovarian cancer cell lines (MCF-7 and 
A2780 cells, respectively) with either paclitaxel or DXL reported dose-dependent increases in 
the production of sTNF-α, which may contribute to the cytotoxic effect of taxanes observed in 
cancer cell lines through the activation of TNFR1- (tumor necrosis factor receptor) -induced 
apoptosis
44
. TNF-α mediated apoptosis, bcl-2 mediated apoptosis and even VEGF down-
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regulation (by production of reactive oxygen species) have all been proposed as downstream 
mechanisms of action for taxanes
44,45
.  
 
The most well-known and characterized of the taxanes is paclitaxel. Currently, however, 
the most promising anti-cancer taxane is the newer agent, DXL. This newer agent shows a 
comparable efficacy to paclitaxel, but it has significantly less and/or different types of toxicity. 
With respect to the binding of β-tubulin, DXL reportedly has an approximately 2-fold higher 
affinity for the β-tubulin binding site compared to paclitaxel33. Although DXL exhibits a more 
manageable toxicity profile than its counterpart, one of the recurrent problems associated with 
the use of these newer agents is the development of drug resistance; a problem encountered with 
all chemotherapeutic drugs used. 
     1.1.4 Pathways Associated with Resistance to Taxanes Agents in vitro and in vivo 
Several important factors such as age, stage of disease and volume of residual disease 
after surgery affect the prognosis of a patient with ovarian cancer. One of the foremost factors 
that has limited the success of chemotherapy in ovarian cancer is the emergence of drug 
resistance in the tumor cell population, although host factors in the patient may be of similar of 
importance
46
. Treatment with taxane agents after surgery usually results in an initial high 
response rate; however, relapse usually occurs, accompanied with acquired drug resistance 
which often includes tumour metastases, contributing to chemotherapeutic treatment failure and 
death for the majority of patients
10
. The initial response rate may be high, due to the death of the 
highly vascularized portion of the tumour from chemotherapy, with relapse occurring due to a 
drug resistant tumour core remaining. This multi-faceted response of the tumor to the treatment 
course prompts us to believe that drug resistance in ovarian cancer is comprised of multiple 
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mechanisms. A large variety of in vitro and in vivo mechanisms of drug resistance have been 
identified. Of the mechanisms that have been characterized (mostly in vitro), frequently observed 
are: suppression of drug entry into tumour cells, active extrusion of drugs from cells, changes in 
P53 pathways, or even enzymatic drug inactivation among others
47,
 
48
. It is even possible for 
drug activity to be prevented by mutated genes or altered expression of proteins important in 
drug acting pathways. Defects associated with apoptosis, cellular senescence, cell cycle 
checkpoints and repair mechanisms have also been reported to contribute to drug resistance
48
.  
In the past 20-30 years of cancer research, studies have shown a tight-knit connection 
between the immune system, cytokines and cancer. Recent studies suggest that tumour necrosis 
factor alpha (TNFα) may be involved in taxane cytotoxicity and resistance. Accordingly, a study 
performed by Sprowl et al.
44
 demonstrated
 
that taxanes can promote dose-dependent TNF-α 
production in tumor cells at clinically relevant concentrations, which can contribute to taxane 
cytotoxicity. Moreover, the study provided evidence that defects in the TNF cytotoxicity 
pathway or activation of TNF-induced NF-κB-dependent survival genes may, in contrast, 
contribute to taxane resistance in tumor cells.  
Some of the mechanisms involved in taxane resistance in vitro and in vivo have been 
identified, although, as is the case for other chemotherapy treatments, resistance to taxanes may 
be multifactorial and has yet to be fully understood. One of the proposed mechanisms of 
resistance to taxanes involves a direct ‘suppression’ of the mechanism of action of the drug; 
involving alterations in microtubule structures of the β-tubulin subunits. Kavallaris et al., 
reported increased expression of β-tubulin isotypes in DXL resistant cells lines and human 
tumours, which supports the importance of changes in specific β-tubulin gene expression in 
contributing to resistance
49
. A clinical study investigating the mechanism of resistance in non-
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small cell lung cancer patients, identified the presence of missense mutations of the β-tubulin 
gene in tumour DNA isolated from patients, which conferred resistance to paclitaxel treatment
50
. 
Based on these studies, it seems that alterations in β-tubulin expression or mutations in the gene 
at the chromosomal level, can affect binding of taxanes to the β-tubulin subunit, allowing for 
some degree of resistance to taxane chemotherapy
51
.  
  Since taxanes have been associated with induction of apoptosis, as previously mentioned, 
another mechanism of taxane resistance is the increased expression of anti-apoptotic genes. In a 
study investigating the sensitivity of MCF-7 breast cancer cells to taxanes, it was observed that 
over expression of the anti-apoptotic genes Bcl-xL and c-FLIP resulted in an increased survival 
of cancer cells to taxanes
52
. Bcl-xL inhibits the intrinsic pathway, and c-FLIP inhibits the 
extrinsic pathway of apoptosis. Therefore, the results from this study suggest that over-
expression of these genes results in increased survival of cancer cells. However, there has been a 
lack of studies demonstrating a direct link to anti-apoptotic mechanisms in an in vivo setting. 
Survivin, which belongs to the inhibitor of apoptosis protein (IAP) family, is another anti-
apoptotic protein which is highly expressed in some cancers, but is undetectable in normal adult 
tissue. Survivin has been shown to block both caspase-dependent and independent death 
pathways
53
. Increased survivin expression in ovarian cancer, as well as increased protein 
expression in tumours of advanced ovarian carcinoma patients have been significantly associated 
with resistance to the agent DXL
54,55
. 
  Another common mechanism of taxane resistance identified in preclinical studies is the 
increased expression of certain types of efflux pumps, which prevent the chemotherapeutic drug 
from accumulating to cytotoxic levels in cancer cells
56
. P-GP (P-glycoprotein) or Abcb1, a 
product of multidrug resistance gene-1 (MDR-1), belongs to the ATP-binding cassette (ABC) 
10 
 
family of drug transporters located on the plasma membrane. These drug transporters are 
responsible for the ATP-dependent efflux of various chemotherapy drugs from tumour cells, 
including taxanes
57
. In cancer cells that are selected for survival in increasing concentrations of 
taxanes, ABCB1 gene amplification is routinely observed as acquisition of resistance is 
achieved
12
. Armstrong et al. reported a significant increase in the expression of the ABCB1 and 
ABCB4 genes in A2780DXL cells, a DXL resistant ovarian cancer cell line that was generated by 
exposing cells to increasing doses of DXL
12
. Similar observations were made in paclitaxel-
resistant SKOV-3 and OVCAR ovarian cancer cell lines, where upon the inhibition of ABCB1 
expression paclitaxel sensitivity was restored
58
.  P-glycoprotein expression has been associated 
in the clinic as a marker and prognostic indicator in advanced ovarian cancer
59
. An association 
between ABCB1 expression and resistance to chemotherapy was also established for ovarian 
cancer patients undergoing paclitaxel treatment, where the presence of a certain ABCB1 single 
nucleotide polymorphisms (SNP) resulted in chemo-resistance and shorter overall survival, 
although this might be linked to a different level of whole body clearance of paclitaxel overall
60
. 
  P53 is a master regulator of ribosomal biogenesis and is a robust sensor of many types of 
nucleolar damage (as well as having the function of a genomic DNA damage sensor)
61
. 
Therefore, mutations and dysfunctions within the P53 pathway have long been associated with 
ovarian cancer
62
. P53 mutations in tumours have also been linked with drug resistant ovarian 
cancer and a shortened survival of patients with advanced resistant disease
63
. However, although 
common, P53 mutations are not required to cause resistance in high grade serous ovarian cancer 
(HGSOC). Hartwitch et al.
64
 have demonstrated that P53 protein aggregation can occur as a 
resistance mechanism to chemotherapy in serous ovarian cancer. The aggregation of p53 protein 
has been discovered in different types of cancers and may be responsible for impairing the 
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normal transcriptional activation and pro-apoptotic functions of p53. Hartwitch demonstrated 
that in a unique population of HGSOC cancer cells with cancer stem cell properties, p53 protein 
aggregation is associated with p53 inactivation and platinum resistance. A novel peptide 
inhibitor of P53 aggregation has even been shown to rescue P53 function to promote tumour 
suppressive properties
65
. 
  Lastly, another reported mechanism of resistance to taxanes has been identified that 
involves increased expression of enzymes capable of metabolizing taxanes. Cytochrome P450 
enzymes, although typically expressed in the liver to metabolize a wide variety of substrates, are 
involved in the metabolism of several anticancer agents, including taxanes
56
. CYP2C8, a 
member of the Cytochrome P450 superfamily of proteins, has been shown to detoxify paclitaxel 
to a metabolite that is approximately 30 fold less cytotoxic 
66
. CYP1B1 has been identified in 
many malignant tumours, and it has been shown that its increased expression is associated with 
metastatic disease. A study investigating CYP1B1expression in vitro and in vivo in epithelial 
ovarian cancer has found an association between increased expression of this  P450 cytochrome 
and lower response rate to paclitaxel treatment
67
. Although there is evidence for a link between 
cytochrome enzymes and ovarian cancer drug resistance, the literature seems to suggest that the 
connection is rather minor. 
  An important and rather overlooked aspect of cancer drug research is the fact that in vitro 
research does not always model what occurs in vivo. In vivo drug resistance to taxanes is often 
associated to the strongly reduced drug delivery to the tumour site due to differences in the 
tumour micro-environment
68
. Poor tumour vascularization, changes in tumour acidity and 
hypoxia along with activation of autophagic survival mechanisms in the poorly vascularized 
tumour are among the most prominent factors that promote tumour survival
69
 in vivo. Recent 
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research is beginning to highlight that the previously mentioned characteristics of the tumour 
microenvironment can be manipulated to improve current therapies
69
. 
 
1.2 The Eukaryotic Ribosome, Ribosome Biogenesis and Ribosomes in a Cancer Setting 
1.2.1. Ribosome composition, structure, function and link to cancer 
Protein synthesis is a fundamental cell process whose proper execution is a critical 
function for regular and healthy cell growth – a statement that applies to all forms of life from 
the prokaryotic to the eukaryotic kingdom. Ribosomes, and particularly the ribosomal RNA 
(rRNA) that displays catalytic ribozymal activity, are the primary and sole effectors of protein 
synthesis. Once a nascent mRNA chain is synthesized in the nucleus from its DNA sequence in 
the genome, it undergoes several possible posttranslational modifications (which include 
capping, cleavage, splicing and polyadenylation). It is then exported from the nucleus into the 
cytosol
70
. Following final modification in the cytoplasm, the ribosomal machinery utilizes 
mature mRNA molecules as templates (recognizing their start and stop codons) to produce new 
polymers of amino acids (proteins), a process termed translation. Although it has been accepted 
as dogma that the cytoplasm (along with mitochondria) is the only site of protein synthesis,  
accumulated evidence is beginning to make a strong argument for nuclear translation
71
. Firstly, 
evidence concerning the destruction of nuclear mRNAs containing premature termination codons 
by nonsense-mediated decay (NMD) is very convincing. NMD is a process in which ribosomes 
scan for mRNAs with premature stop codons and mark them for degradation. The only known 
way to detect termination codons is by the ribosome, and as some NMD occurs within the 
nuclear fraction, active nuclear ribosomes could perform the required detection
72
. There is also 
13 
 
the evidence that tagged amino acids are incorporated into nascent polypeptides in a nuclear 
process coupled to transcription as well as the fact that components involved in translation, 
NMD and transcription co-localize, co-immunoprecipitate and co-purify
73
.  
The eukaryotic ribosome is a large “80S” macromolecular complex of proteins and 
rRNAs, where 80S refers to its sedimentation coefficient in Svedberg units upon centrifugation 
in sucrose density gradients.  The 80S ribosome is composed of large (60S) and small  (40S) 
subunits, with the larger subunit being of approximately twice the size of the small
74
. Both 
subunits are composed of a complex, folded 3D structure of rRNAs that have ribosomal proteins 
(RP) bound to their exterior structure. The eukaryotic human large subunit contains the 28S, 5.8S 
and 5S rRNAs, which are 5025 nucleotides (nt), 160 nt and 120 nt, respectively.  The small 
subunit contains the 18S rRNA, which is 1900nt 
75
. The primary catalytic function of the 
ribosome is located within the 28S rRNA itself (in the peptidyl transferase center). The 18S 
rRNA functions as the decoding center, bringing together aminoacyl-tRNA molecules and 
mRNA codons that are complementary to each other.  It is generally accepted that the RPs most 
likely help with the folding of the rRNA and certain other accessory functions in translation; 
some of which have been identified
74
. The various ribosomal proteins and rRNAs will be 
described in detail in sections to follow. The large subunit has approximately 46 RPs while the 
small subunit has approximately 33 RPs adhered to their respective rRNAs
76
 (See Appendix 
Figure 17). 
There are three global steps that allow for protein synthesis to occur at the ribosome: 
initiation (with the help of initiation factors, the mRNA binds to the small subunit of the 
ribosome), elongation (the GTP-dependent process of recruiting amino-acyl tRNA to shuttle the 
new peptide through the aminoacyl, peptidyl and exit (APE) sites (See Appendix Figure 15) of 
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the ribosome with the help of elongation factors) and termination (the release of the nascent 
polypeptide chain with the aid of release factors at UAA or UAG stop codons)
77
. There are about 
20,000 – 25,000 protein-coding genes in the human genome, with recent evidence suggesting the 
number may be as low as 19 000
78
. Protein products for about 18,000 of these genes have been 
detected in at least one human tissue. About 10,000 of these proteins are present in all cells and 
between 1500 and 2000 proteins are derived from genes that are essential for cell function
79
. 
Every single one of these proteins is produced, in a regulated manner by the sub-cellular 
machinery that we call the ribosome. Therefore, the generation of mRNA molecules and proteins 
occurs in a coordinated and regulated manner to allow the expression of specific amounts of 
proteins at specific times in the cell cycle to allow for the coordinated process we call life. 
Evidence is starting to highlight the fundamental differences in ribosomes between 
different organisms and also the ribosome variability within a species
75,80
. However, most 
striking is that we are now beginning to shed light on ribosome structural heterogeneity within 
different tissues of the same organism
81
. Historically, the ribosome was viewed as an 
unchangeable entity, constantly equipped with the entire complement of RNAs and proteins to 
translate all proteins in an unbiased manner. Conversely, several lines of evidence indicate the 
presence of functional selective ribosomal subpopulations in bacteria that exhibit variations in 
the RNA or the protein components and modulate the translational program in response to 
environmental changes
82
. Therefore, although ribosomes were shown to be effectors of 
translation 40 years ago, it has only recently become apparent that they also act as regulators. 
During evolution, ribosomes from higher eukaryotes have selected additional RPs and rRNA 
segments that are not directly involved in mRNA decoding and peptide formation, but are 
predicted to support regulatory events
83. As the ‘relative complexity’ of an organism increases, 
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in general, a corresponding increase in the size of the rRNAs and the numbers of associated 
ribosomal proteins is observed. Also, ribosomes with variable composition have been identified 
that support distinct translational activity depending on cell type or in response to viral 
infection,
84
. In addition, changes in ribosome composition (termed ribosomopathies) result in 
developmental defects in both animals and humans while having no, or only a weak, effect on 
the survival of cultured cells
85
.  
Ribosome heterogeneity is a fascinating field of science that is just in its beginnings and 
when we start to apply this theory in the presence of dysregulated cell growth, i.e. cancer, it 
becomes even more intriguing. The concept of differential regulation of translation at the 
ribosome is supported by a recent genome wide profiling study
86
, that has demonstrated the 
heterogeneity of ribosome composition and how this affects the translated population of mRNA 
molecules. Recent research reviewed by Lafontaine (2015) has also shown that rRNA 
heterogeneity can regulate translation to generate distinct translatomes, which can promote 
tumorigenesis
87
. 
Some cancer scientists are now beginning to shift the way they view cancer as a 
disease
88
. Classically, cancer is thought to be a disease that is most often caused by accumulation 
of mutations or other alterations to nuclear DNA.  However, nucleolar morphology (the site of 
rRNA synthesis) is used by some pathologist to predict clinical outcome of cancer
89
. There is 
evidence that the nucleolus is the starting point of a series of metabolic changes that characterize 
cancer cells. In a typical healthy cell, the nucleolus is a key cellular sensor to stress and plays a 
central role in P53 activation
61
. In cancer cells, cell entry into the cell cycle is always associated 
with up-regulation of nucleolar function, increased nucleolar size, and increased synthesis of 
ribosomes, which are also directly dependent on the rapidity of cell cycle progression
89
. Also, 
16 
 
alterations of the tumour suppressor retinoblastoma (Rb) and p53 pathways contribute to the 
stimulation of nucleolar function and to nucleolar enlargement, which have been attributed to 
greater aggressiveness of cancer tissues
89
. This accumulating evidence suggests that cancer is a 
disease significantly affected by the activity of the ribosomal compartment
90
. Just recently, 
disruption of ribosome biogenesis with an agent known as a small molecule inhibitor of RNA 
Polymerase I transcription, CX-5461, has shown unexpected, potent, and selective killing of 
tumor cells via disruption of nucleolar function leading to activation of p53, independently of 
DNA damage
91
.  
Recent studies have also begun to highlight the fundamental roles that previously 
identified, important oncogenes such as MYC, RAS, MTORC1 and PI3K play in driving RNA 
Polymerase I transcription in the nucleolus
92,93,94,95
, which is a master orchestrator of ribosome 
biogenesis. In addition to maintaining essential levels of protein synthesis, hyper-activated 
ribosome biogenesis and nucleolar function play a central role in suppressing p53 activation in 
response to oncogenic stress
96
. It has now been shown that cells with enhanced tumour 
aggressivity display a marked increase in the synthesis of various rRNA precursors with 
activation of alternative pre-rRNA synthetic pathways, a decrease in the regulation of P53 
mRNA, along with enhanced post-transcriptional methylation of specific sites located with the 
28s RNA molecule
97
 
1.2.2 Ribosome Biogenesis: rRNA loci, rRNA gene transcription, and rRNA processing in 
nucleoli 
Ribosomes are necessary for the production of all proteins found within the cell. 
Therefore the energy and effort that a cell must dedicate to the production of these protein 
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factories is actually quite substantial
76
. In eukaryotic cells, ribosome biogenesis recruits all three 
RNA polymerases, requires the work of over 200 transiently associated ribosome assembly 
factors and the sequential importing of many ribosomal proteins within the nucleolus and 
nucleus followed by the export of ribosomal particles and pre-ribosomes to the cytosol. The 
process all begins within the nucleolus, which is the largest visible structure within the nucleus. 
The nucleolus is an amalgamation of protein and RNA which forms around specific genetic loci 
termed nucleolar organizer regions (NOR) which are tandem repeats of rDNA. Specifically, they 
contain the genetic information for the 28S, 18S and 5.8S rRNA which, in humans, are clustered 
on chromosomes 13, 14, 15, 21 and 22
98
. In other words, the nucleolus is like an organelle 
formed by the act of building a ribosome and that its structure does not need to be maintained for 
proper function
98
.  
RNA polymerase I transcribes the long 47S rRNA precursor molecule which contains the 
three aforementioned rRNA molecules along with spacers in the following order: 5’ ETS 
(externally transcribed spacer), 18S rRNA, ITS1 (internally transcribed spacer), 5.8s rRNA, 
ITS2, 28S rRNA and the 3’ ETS. The mature human rRNA transcripts are generated by a series 
of complex cleavage and maturation steps, many of which still remain to be understood
76
 and are 
inferred to exist based on evidence from experiments in other organisms. It is currently known 
that multiple processing pathways exist during the processing of rRNA in humans, although it is 
not specifically known which pathways are active/utilized. The endonuclease responsible for 5’ 
ETS cleavage still remains to be found, whereas the degradation of the 5’ ETS primarily requires 
the cooperative action of the 5′ →3′ exoRNase XRN2 and the exosome in mammalian cells76. In 
humans, it has been shown that the exosome is necessary for the cleavage and degradation of the 
ITS1, which aids in the generation the mature 18S subunit along with NOB1 (processing factor) 
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which trims the 18S RNA in the cytoplasm
99
. The 5.8S rRNA maturation process is assisted by 
the RNA helicase Dob1p/Mtr4p, which functions in unwinding the secondary structures or 
displacing the bound proteins that may otherwise hamper progression of the function of the 
exosome
100
. The exosome initiates cleavage (with the help of exosome-associated factors MTR4, 
C1D and MPP6) and trimming of the 5.8S RNA with the Rrp6 exo/endo-nuclease subunit of the 
exosome in the ITS2 region to release the mature rRNA
100
. In terms of the maturation of the 28S 
subunit in humans, the exonuclease XRN2 ensures the trimming of the 5’ end of the rest of the 
ITS2
101
. 
The 5S rRNA on the other hand is transcribed in the nucleus from chromosome 1 in an 
independent fashion as a 3’ end-extended precursor by RNA polymerase III (Pol III)75. The 
presence of 5S rRNA is required for normal translation in most ribosomes, although its exact 
function within the ribosome is unclear. The 5S rRNA remains the most elusive of all rRNAs 
regarding its precise function and how this correlates with structure. However, it is thought to 
play a critical role in both protein–RNA and RNA–RNA interactions within the ribosome102. 
RPLa and RPL5 have been shown to be necessary pre-ribosomal binding proteins that facilitate 
the maturation of the 5s rRNA, which then allows it to be exported to the cytoplasm
102
. It is 
known that yeast exonucleases process the 3’ section of 5S rRNa although this has not been 
extensively studied in humans. The 5S rRNA can be polyadenylated and subsequently degraded 
by the exosome. Interestingly, nucleotides in eukaryotic 5S rRNA are rarely pseudouridylated 
and methylated by H/ACA and C/D Box snoRNAs
102
.  
During the various cleavage and processing steps mentioned above, it has been shown 
that various snoRNAs (small nucleolar RNAs) are active in the form of snoRNPs (small 
nucleolar ribonucleoparticles) that play important roles in the generation of rRNA transcripts.  
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However, we are just beginning to elucidate their implications. Lafontaine recently reviewed the 
current knowledge of over 200 snoRNAs involved in ribosome biogenesis
87
. SnoRNAs are 
small, abundant and stable RNAs of ancient origin that localize to the nucleolus at a steady state 
and are found in all eukaryotes. snoRNAs act in pre-rRNA modification, processing and folding 
through typical Watson-Crick base pairing with their substrate RNA sequences. All three classes 
of snoRNAs (box C/D, box H/ACA and MRP) are all active as snoRNPs in tight association with 
conserved core proteins
87
. It is mostly C/D and H/ACA snoRNPs that drive RNA modification. 
Box MRP is mainly involved in rRNA processing (ITS1 removal)
87
. BOX C/D and H/ACA 
snoRNAs range in size from 60-250nt and are associated with four core proteins; among which 
are the enzymes that mediate rRNA modification
103
. Box C/D snoRNPs methylate the 2'-
hydroxyl moiety to form  a 2'-O-methylated nucleotide of rRNA with the help of the 
methyltransferase Fibrillarin, while box H/ACA snoRNPs mediate the pseudouridylation of 
specific uridine residues in rRNA using the pseudouridine synthase Dyskerin
104
,
103
. Considering 
that each human ribosome contains 200 total modifications (around 100 ribose methylations and 
100 pseudouridines), and considering that each position is subject to individual regulation 
through specific snoRNA guides, the combinatorial potential is immense. Therefore, it can be 
argued that snoRNA-mediated rRNA modification, is one of the most prominent sources of 
ribosome heterogeneity, as discussed in the previous section
87
. Interestingly, the biogenesis of 
certain snoRNAs (along with Fibrillarin) was found to be essential for the development and 
progression of breast cancer in vitro and in vivo
105
. This highlights the molecular involvement 
and implications of P53, the nucleolus, and the ribosome in tumorigenesis. 
Clusters of human ribosomal DNA (rDNA), which code for rRNAs,  exhibit great 
variability in length (50kb to >6Mb) and composition, manifest complete heterozygosity, and 
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provide each person with their own unique rDNA electrophoretic karyotype
75
. By analyzing 
multigenerational families, Stults et al. discovered that the rDNA clusters are subject to meiotic 
re-arrangement at a frequency >10% per cluster, per meiosis. This suggests that rDNA clusters 
themselves demonstrate a very high level of genomic plasticity, and when combined with the 
snoRNA mediated rRNA combinatorial modifications and diversity in RPs, there can be no 
doubt of a very substantial ribosome heterogeneity.  
1.2.3 Ribosomal proteins, function, localization and connection to apoptosis 
Ribosomal proteins are synthesized by the translating macromolecular machine itself (the 
ribosome). This tends to raise the typical “who came first” story: the chicken or the egg? It is 
quite evident, but somehow confusing that functional ribosomes translate their own proteins that 
will be then integrated into the next generation of synthesized ribosomes. These newly 
synthesized RPs are then imported into the nucleus/nucleolus and have been implicated in the 
maturation of pre-rRNA molecules
74
. Most RPs are small enough to passively enter the nucleus 
(7-70kDa); however, their import is facilitated by nuclear transporters that recognize their 
nuclear localization signals along with several chaperones specific to certain RPs
74
. The precise 
functions of RPs in pre-rRNA processing along with ribosome biogenesis remain elusive. X-ray 
crystallography and cryo-electron microscopy (EM) structures of mature ribosomes have shown 
that most RPs share common structural features, in particular globular domains interspersed by 
poorly structured loops that bind to rRNA or other RPs
106
 (See Appendix Figure 17). In 
eukaryotes, we especially observe that RPs contain tails extending from their globular domains. 
Several of these extensions protrude far into the rRNA, while most pass across the surface of the 
ribosomal subunits contacting multiple secondary structures within the rRNA sequence
74
. This 
suggests the strongly basic RPs play a crucial role in bringing and/or keeping rRNA domains 
21 
 
together
74
. Studies in prokaryotes and eukaryotes indicate that the interaction network between 
proteins and RNA commences loosely and dynamically, gradually tightens as subunit assembly 
occurs, and eventually forms translating cytoplasmic ribosomal subunits
107
. It is generally 
thought that during subunit assembly RPs function as chaperones assisting the proper folding of 
the nascent pre-rRNA molecules. Only recently have the implications of RPs in ribosome 
biogenesis been investigated, because typical efforts to study ribosome biogenesis were focused 
on the processing of pre-rRNAs, ribosome structure and assembly co-factors with most of the 
studies performed in yeast and bacteria. 
Indeed, in vitro assembly of bacterial ribosomes have shown that RPs are required in a 
hierarchical order
108
. RPs that are necessary for the early steps of 28S pre-rRNA processing are 
located on the exposed surface of the large subunit of the ribosome, mainly bound to domains I 
and II of the 28S rRNA
109
. The group of RPs required for the intermediate steps of 28s rRNA 
processing tend to be located near the polypeptide exit tunnel of the mature ribosome, on 
domains I and III of both the 28s rRNA as well as the 5.8S rRNA. RPs involved in early 
processing of the 5.8S rRNA are located on the large and small subunit interface and those 
required for late steps of maturation cluster around the central protuberance of ribosomes
109
 (See 
Appendix Figure 16). 
As was discussed briefly, the nucleolus and therefore ribosome biogenesis is a strong 
sensor of cellular stress. Ribosomal proteins are known to interact with the P53 pathway to 
mediate this stress signal. It is important to note that MDM2 regulates p53 in two ways. MDM2 
binds directly to p53, preventing its transactivation domain from accessing the transcriptional 
machinery. MDM2 also acts as an E3 ubiquitin ligase for its conjugate p53, mediating the 
ligation of ubiquitin to p53 and its subsequent degradation by the proteasome
61
. A plethora of 
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events imparting instability to the ribosomal biogenesis process can cause nucleolar stress. As a 
response to this stress, the increase in free ribosomal proteins can bind to MDM2 and block 
MDM2-mediated p53 ubiquitination and degradation, resulting in p53-dependent cell cycle 
arrest
110
.  By enabling the arrest of the cell cycle, the ribosomal proteins play a crucial role in 
connecting deregulated cell growth with inhibition of cell division; a process which becomes 
dysregulated in cancer. A variety of settings and agents (serum deprivation, chemical agents, 
oxidative stress, and ribosome malfunction) have been shown to generate nucleolar stress that 
signals to p53
61
. This allows cells to halt proliferation under unhealthy and poor ribosomal 
biogenesis conditions, a function necessary to ensure healthy growth of the organism and tissues. 
To date, several RPs, including RPL11
111
, RPL23
112
 and RPL5
113
, have been found to activate 
p53 through their interactions with MDM2. 
By inhibiting ribosome assembly in a stressed cell setting, there is less ribosomal protein 
binding to the rRNA and there is an increased binding of RPL5, RPL11, and RPL23 to MDM2. 
This binding inhibits MDM2 function, resulting in p53 accumulation and activation. In addition 
to the three aforementioned RPs, RPS7 and RPL26 have also been shown to interact with 
MDM2
114,115
. The consequence of the RPS7-MDM2 interaction resembles that of the 
aforementioned three RPs in terms of their mechanism of action in binding MDM2 and 
activation of p53. This stress induced loss of RPs from ribosomes would also expose the 
underlying rRNA to degradation, as discussed in the next sub-section. 
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1.3 Ability of Chemical Agents to Inhibit Ribosome Biogenesis and Affect Ribosome 
Integrity 
1.3.1 Cell death inducing agents: rRNA disruption and ribosome biogenesis disruption 
It has been known for several decades that cell death inducing agents, specifically 
apoptosis inducers, often result in the ordered laddering and degradation of DNA through the 
cleavage and activation of caspases that in turn activate caspase-activated DNases (CADs). The 
link of chemical and apoptotic inducing agents with the cleavage of rRNA was initially observed 
after many studies had established the link between DNA cleavage and apoptosis.  Early work on 
apoptosis-inducing agents and RNA cleavage was  performed by Houge et al., who demonstrated 
that several cytotoxic agents (okadaic acid, prednisolone, cycloheximide, and camptothecin, 
among others) could induce specific 28S and 18S degradation fragments in a variety of 
eukaryotic cell types 
116
,
117
. These agents induce 28S rRNA cleavages in regions known as 
variable or divergent domains
118
. Also known as expansion segments
119
, these regions have 
greater sequence variability than highly conserved regions. In mice thymoma cell lines treated 
with a calcium ionophore, rRNA degradation was observed in the absence of caspase activation 
and in a Bcl-2 independent manner, suggesting that apoptosis induction may not be necessary for 
rRNA degradation to occur
120
. Since these earlier studies, various other cell death inducing 
agents, including a variety of mycotoxins, have been shown to elicit the response of ordered 
disruption of the 28s rRNA
121,122
. Regardless of the type of cell death, rRNA has been shown to 
be an early cellular target affected by various cell death-inducing agents in a variety of 
eukaryotic cell types. Unfortunately, the molecular mechanisms mediating the cleavage of the 
28S rRNA remain elusive. 
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DNA damage has long been known to activate p53 through a variety of mechanisms.  
However, studies by Rubbi and Milner suggests a connection between DNA damage and 
activation of p53 through rRNA-related pathways. In an experiment in which directed DNA 
damage was generated using localized UV irradiation, p53 was not activated when the nucleolus 
remained unaffected. The investigators concluded that DNA damage alone cannot activate p53 
and that nucleolar disruption is a prerequisite for p53 activation
123
. Therefore, to effectively 
initiate apoptotic cell death through P53 and nucleolar disruption, ribosome biogenesis disruption 
may be necessary
124
. Agents such 5-Fluorouracil and bleomycin have been shown to interrupt 
ribosome biogenesis and cause P53 activation
123
. A survey study of various chemotherapy agents 
that were previously unknown to interfere with ribosome biogenesis, has demonstrated that many 
chemotherapeutic/cytotoxic agents also cause ribosome biogenesis disruption at various levels 
within rRNA biogenesis
125
. This evidence points to the nucleolus as being an early sensor of 
cytotoxic onslaught, with the rRNA and ribosomes being regulated by cleavage, as just 
discussed. However, the mechanisms involved in regulating the interplay between ribosome 
biogenesis disruption and rRNA cleavage are unknown, as is the timeline that occurs between 
the two, if any. 
1.3.2 Ribosomal Integrity as an Indicator of Response to Several Chemotherapy Agents 
Quite recently, Narendrula et al.
126
 have determined that several ovarian and breast 
cancer cell lines (A2780, CAOV-3, MCF-7, SKBR-3, MDA-MB-231) reproducibly demonstrate 
significant rRNA disruption when treated with a variety of chemotherapy agents with succinctly 
distinct mechanisms (DXL, paclitaxel, carboplatin, cisplatin, vincristine, irinotecan and 
etoposide). The authors also report that there is an absence of rRNA cleavage products when 
cells are treated with a drug to which they are resistant. DXL was shown to be one of the most 
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reproducible and robust agents to induce rRNA degradation in this study
126
. This demonstrates 
that chemotherapy triggered cell death involves the degradation of rRNA, and that this appears to 
be a measure of the sensitivity of the cell line to the administered drug. 
Since the discovery of taxanes as microtubule disruption agents, it has since been 
assumed that they elicit their cytotoxic activity through the induction of apoptosis subsequent to 
the stabilization of β-tubulin subunits by the drug34. However, as Burger et al. have shown, many 
other chemotherapy agents with different mechanisms also inhibit ribosome biogenesis at 
various levels
125
. DXL is used to treat a variety of cancers
41
 and it is therefore of great 
importance to determine whether other pathways induced by the drug contribute to cell death.   
 
1.4 Reviewing Possible Mechanisms Involved in rRNA Degradation   
      1.4.1 Early research and links to apoptosis 
RNA degradation, in particular degradation of the 28S rRNA into distinct fragments, had 
been observed earlier by Houge et al. and was found to coincide with DNA fragmentation, a 
hallmark of apoptosis
116,127
. The association between RNA degradation and apoptosis was also 
observed in oat cells, undergoing cell death as a result of exposure to a host-specific toxin, 
victorin, produced by the fungus Cochliobolus victoriae
128
. As a result of apoptosis induction in 
developing rat cerebellum, degradation of both the 28S rRNA and 18S rRNA was observed with 
DNA fragmentation, demonstrating yet again that rRNA degradation often occurs with apoptosis 
induction
129
. A strong piece of evidence that linked apoptosis with rRNA degradation were the 
findings of Nadano et al. which showed that activating Fas receptor with an anti-Fas antibody  
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could produce rRNA degradation patterns
130
. Quite recently He et al. have demonstrated that the 
mycotoxins deoxynivalenol as well as satratoxin, anisomycin and ricin selectively cleave the 28S 
rRNA, and is related to apoptosis. This cleavage can be abrogated by inhibiting P53
131
. 
1.4.2. RNase L and other RNases as candidates of rRNA disruption 
Cellular RNA is highly stable, and its transcription and degradation are under many 
levels of control. RNA-degrading enzymes called ribonucleases (RNases) interact with co-
factors such as helicases, polymerases and chaperone proteins, to promote the degradation of 
messenger RNA (mRNA), transfer RNA (tRNA) and rRNA, through highly controlled 
processes
132
. Approximately 80% of the total RNA content of eukaryotic cells consists of 
rRNA
133
, and although to date there has been little evidence to demonstrate rRNA cleavage by 
RNases in human cells, one can postulate that several degradation processes and therefore 
several RNases would be in place to cleave ribosomes that are dysfunctional and/or in a cell 
stress setting. 
One RNase that has been implicated in the cleavage of rRNA is RNase L. RNase L was 
initially discovered as an RNase implicated in an interferon-mediated antiviral response 
mechanism involving the activation of 2′,5′-oligoadenylate (2-5A) synthetase (OAS). Once the 
host is infected with an RNA virus, interferon gamma (IFN) is produced.  IFN induces RNase 
L production and activates OAS, which, in turn, activates the induced RNase by promoting 2-5A 
production. This cleaves both the viral and host cellular RNAs
134
. RNase L is one of the key 
enzymes involved in the function of interferons (IFNs), a family of cytokines participating in 
innate immunity against viruses and other microbial pathogens. Upon binding with its activator, 
2-5A, RNase L degrades single-stranded viral and cellular RNAs and thus plays an important 
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role in the anti-viral and anti-proliferative functions of IFNs
134
. Zhou et al. have shown a 2‐fold 
decrease in apoptosis in vivo in the thymuses and spleens of RNase L
−/−
 mice
135
. Furthermore, 
apoptosis was substantially suppressed in RNase L
−/− 
thymocytes and fibroblasts treated with 
different apoptotic agents. These results suggest that both interferon action and apoptosis can be 
controlled by the activity of RNase L. Additionally, RNase L induction was shown by Han et al. 
to cause cleavage of mature rRNA products in Hela cells due to the 2-5A response, which was 
similar to virally induced cleavage
136
. Very recently, a doxifluridine conjugated 2-5A analog of 
2-5A was shown to have even greater activation ability than 2-5A itself for RNase L and has 
demonstrated potent anticancer activity against cervical cancer cells
137
. This research was critical 
at demonstrating a link between RNase L induction and suppression of cancer using an 
endogenously activated RNase, although its mechanism of tumour suppression is unknown.  
Malathi et al. have also demonstrated that small dsRNAs produced by RNase L promote 
a switch from autophagy to apoptosis by caspase-mediated cleavage of Beclin-1, terminating 
autophagy
138
. Cleavage of Beclin-1 inhibits autophagy and the C-terminal fragment translocates 
to the mitochondria along with the pro-apoptotic protein, Bax, promoting the release of 
cytochrome C to the cytosol and inducing apoptosis. This demonstrated a clear link between 
RNase L decay products and apoptosis and demonstrates the importance of trying to identify 
decay products of endogenous RNases. 
Another possible RNase candidate to explain RNA disruption previously observed by 
Narendrula et al.
126
 and others is IRE1. The serine/threonine protein kinase/endoribonuclease 
inositol-requiring enzyme 1 (IRE1) is an ER transmembrane sensor that activates the unfolded 
protein response to maintain the ER and cellular function. Although mammalian IRE1 promotes 
cell survival, it can initiate apoptosis via decay of anti-apoptotic miRNAs
139
. IRE1 has been 
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shown to induce translational repression through 28S ribosomal RNA cleavage in response to ER 
stress
140
. Specifically IRE1β mediates the site-specific cleavage of 28S rRNA and translational 
attenuation of protein synthesis through its endonuclease function. Although there has not been a 
link between chemotherapy induced RNA degradation and IRE1 activation, it remains a 
possibility. 
1.4.3 The exosome or NRD as potential mechanisms involved in rRNA disruption 
To ensure that ribosomes are accurately synthesized and carry out their function properly, 
an active surveillance system exists that recognizes aberrant or stalled pre-ribosomes and targets 
them for degradation. Research by Allmang et al.
141
 and Mitchell et al.
142
 has demonstrated that 
pre-ribosomes which accumulate in the nucleus are degraded by the exosome. The exosome or 
exosome complex (sometimes abbreviated PM/Scl) is a multiprotein complex capable of 
degrading a variety of RNA substrates. The core of the exosome contains an inactive six-
membered ring structure to which other RNases and proteins are attached
141
. Eukaryotes also 
contain an additional three core subunits, which form a structural cap that bridges the ring 
structure. Dis3 and Rrp6 constitute the associated RNases
143
. In eukaryotic cells, the exosome 
complex is present in the cytoplasm, nucleus and especially the nucleolus where nuclear pre-
rRNAs (by the addition of a 3’ oligo-A tail) can be degraded. In vivo exosome activity is 
regulated by associated enzymatic cofactors and RNA-binding adapters, which facilitate 
exosome access and recruitment to a multitude of substrates. The most characterized cofactor 
which aids the exosome is the Trf4p/5p-Air1p/2pMtr4p polyadenylation or TRAMP complex
144
. 
The exosome has been shown to demonstrate exoribonucleolytic function as well as 
endoribonucleolytic function in humans
145,146
. The most recent research is beginning to show that 
the human nuclear exosome is necessary for the proper cleavage and maturation of the rRNA 
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precursor molecule at site A2, which is necessary for removal of the internally transcribed spacer 
1 or ITS1
99
. Quite recently Thoms et al. have also shown that the exosome plays a key role in the 
cleavage and removal of the ITS2 sequence from the end of 5.8S rRNA
100
. Although it is not 
clear how the exosome may play a role in chemotherapy induced RNA degradation, it is 
conceivable that some of these pathways may be involved due to their tight knight involvement 
in human ribosome biogenesis. 
Non-functional RNA decay, abbreviated NRD, has been shown to degrade rRNA in 
ribosomes with a non-functional 28S subunit (mutated Peptidyl Transferase Center) by Lariviere 
et al
147
. These experiments indicate that the non-functional rRNAs are produced and 
incorporated into ribosomes similarly to wild-type rRNAs, but are then degraded faster by NRD 
following the completion of rRNA processing and ribosome assembly. Studies involving large 
subunit ribosomal NRD have shown that ubiquitylation levels are strongly increased and that this 
may play a strong role in the activation of NRD
148
. Fuji et al. have also demonstrated that this 
specifically requires the proteins Mms1 and Rtt101, which seem to localize to specific 
perinuclear locations
148
. The mechanism of RNA degradation in NRD is not known, although it 
is speculated that the exosome may play a role. rRNA is the most abundant nucleic acid in cells 
and although it is quite stable, is susceptible to damage from chemicals, ROS and stress. 
Furthermore, toxins like sarcin, ricin, and other ribosome-inactivating proteins depurinate rRNA, 
rendering the ribosomes nonfunctional
149
. Thus, NRD likely exists to clear the cell of rRNAs that 
have been damaged in a variety of manners.  
One thing that remains clear is that although the rRNA of defective ribosomal particles 
has been extensively studied and shown to be submitted to regulation by distinct mechanisms, 
the fate of the ribosomal proteins from the defective ribosomes remains unclear. It also remains 
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unknown what mechanism is being employed by a variety of mechanistically distinct anti-cancer 
agents to induce rRNA degradation 
1.5 Monitoring the Ribosome to Predict Chemotherapy Outcome 
      1.5.1 The Ribosome as an early sensor to chemotherapy 
Typically, chemotherapeutic agents were selected on the basis of certain rudimentary 
properties that were initially identified as crucial to kill rapidly dividing cancer cells by 
damaging or stressing cells to initiate apoptosis: interference with DNA metabolism, drug-
induced DNA crosslinking or production of ROS. Classically, cancer is thought to be a genetic 
disease that is most often caused by accumulation of mutations and damage wrought on DNA 
within the nucleus of cells.  However, as was previously mentioned, evidence is now beginning 
to be shed that demonstrates that disruption of normal ribosomal function can contribute to the 
development of cancer as a disease as well
88
. When it comes to chemotherapy treatment, Burger 
et al. demonstrate that multiple chemotherapeutic drugs inhibit ribosome biogenesis at various 
levels, which rather contradicts our current understanding of the mechanisms of action of certain 
chemotherapeutic agents
125
. The authors of this study evaluated the synergism of drugs inhibiting 
rRNA synthesis at different levels. Drugs inhibited rRNA synthesis at several levels, including: 
rRNA transcription (e.g. oxaliplatin, doxorubicin, mitoxantrone, and methotrexate), early rRNA 
processing (e.g. camptothecin, flavopiridol, roscovitine) and late rRNA processing (e.g. 5-
fluorouracil, MG-132, homoharringtonine). It was reported that inhibiting rRNA transcription or 
early rRNA processing steps caused nucleolar disintegration, whereas blockage of latter rRNA 
processing steps did not affect nucleolar integrity. There has even been recent research interest in 
blocking eukaryotic initiation factor 4F (EIF4F), which is responsible for recruiting mRNA to 
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the ribosome during protein production
150
. Cencic et al reports that an EIF4F inhibitor greatly 
sensitizes cancer cells to chemotherapy agents in several settings
150
. With this emerging 
evidence, many are starting to now understand that inhibition of ribosome biogenesis by 
chemotherapeutic drugs potentially may contribute to the efficacy of therapeutic regimens. 
Because of the ability of chemotherapy agents to induce damage to the ribosome and ribosome 
biogenesis intermediates, the ribosome therefore has promising potential to become a new way to 
measure the efficacy of chemotherapeutic agents, as well screening for potential new drug 
candidates. With this in mind, it would also enable the ribosome and its integrity as an early 
sensor/monitor to chemotherapy treatment.  
      1.5.2 RDA; a tool using rRNA integrity to predict patient response 
Recently, a Toronto based company, RNA Diagnostics was founded based on a study 
(the CAN-NCIC-MA.22 clinical trial)  which monitored rRNA integrity in women with locally 
advanced or inflammatory breast cancer treated with epirubicin and DXL at 2 or 3 weekly 
intervals in sequential cohorts
151
. Breast biopsy cores were obtained from 50 patients pre-, mid-, 
and post-treatment and the relationship between various biomarkers and treatment response was 
assessed. It was determined that a low mid-treatment tumour RNA Integrity Number (RIN) of 
samples correlated with pathological complete response (pCR) post-treatment, suggesting that 
tumor RIN may represent an important new biomarker for measuring response to chemotherapy 
in breast cancer patients. Rna Diagnostics, Inc. have since developed the RNA Disruption Assay 
(RDA), which uses a proprietary algorithm to quantify the creation of high molecular weight 
rRNA degradation products in tumours (RNA disruption) early in chemotherapy treatment
152
. A 
biopsy is taken during chemotherapy treatment and the amount of RNA disruption expressed as 
an RNA disruption index. When rRNA is sufficiently disrupted, tumour cells can no longer make 
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proteins and other substances necessary for cell division. When rRNA disruption is more 
extensive, cells can no longer maintain basic functions and die. Thus, it appears that tumour cells 
can only tolerate a small level of RNA disruption, above which they become non-viable
152
.  
This could be very useful as a “chemoresponse” assessment tool.  If chemotherapy is 
working (as measured by RDA), the physician and patient can continue chemotherapy with 
confidence. However, if chemotherapy is not working well enough, physicians may consider 
alternate therapies. For the cancer patient, this allows for the avoidance of harmful side effects 
from ineffective chemotherapy regimens and an opportunity for improved survival outcomes. 
This tool would allow physicians to identify non responding patients, typically those that develop 
chemo-resistance within the cancer, and ultimately help guide cancer care. Thus, rRNA 
degradation may now be a useful new tool to monitor the progress of chemotherapy treatment 
and predict patient outcome. However, there is a still a great lack of knowledge of how 
chemotherapeutic agents affect ribosomes structure and promote the degradation of rRNA. 
1.5.3 Implications of ribosomal proteins and their facilitation of rRNA degradation: 
monitoring ribosomal proteins following chemotherapy administration 
As it has been previously stated, chemotherapeutic agents cause the ordered degradation 
of rRNA in cancer cells
126
. The degradation of rRNA can be monitored to evaluate tumour 
response to specific chemotherapy regimens and to predict patient outcome after treatment
152
. 
However, it is also known that the ribosome is a macromolecular complex composed of several 
rRNAs and multiple ribosomal proteins. In previous investigations of ribosomal proteins, there 
have been several independent research projects that have demonstrated the implication of 
ribosomal proteins in the maintenance and regulation of the cell cycle as well as the progression 
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to apoptosis. Repression of a large portion of 60S and 40S ribosomal proteins in a yeast model 
induced cell cycle arrest in either the G1 or G2/M phase of the cell cycle
153
. Interestingly, Thapa 
et al. also found that the ribosomal proteins whose repression generates similar effects on cell 
cycle progression, cluster in the same area of ribosome physical structure, allowing the authors to 
infer that different topological areas of the precursor and/or mature ribosome are mechanistically 
connected to separate aspects of the cell cycle. This could mean that to induce specific cell 
cycles changes (i.e. cell death through a defined pathway/mechanism), a specific ribosomal 
protein (or a specific subset of ribosomal proteins) may need to have an altered expression level 
or be degraded. Therefore, it is likely that changing the expression or activity of specific 
ribosomal proteins would be expected to have significant effects on the cell. 
There have been several ribosomal proteins that have been shown to regulate the cell 
cycle and apoptosis through their expression levels. Abnormal expression levels of ribosomal 
protein L7 in Jurkat T-lymphoma cells has been shown to arrest the cell cycle in G1
154
 and to 
induce apoptosis. Expression of L13a in humans was shown to interfere with cell cycle 
progression by arresting the cell cycle in G2/M phase and inducing apoptosis, while inhibition 
caused apoptosis as well
155
. Naora et al. have also shown that human ribosomal protein S3a 
(RPS3a) plays important roles in cell transformation and death. Constitutive or transiently 
enhanced RPS3a expression primes a cell for apoptosis, whilst the suppression of enhanced 
expression acts as the execution signal of the cell
156
. Knockdown of ribosomal protein S15a was 
shown to induce apoptosis in a human glioblastoma cell model
157
. The examples of ribosomal 
protein expression changes resulting in apoptotic cell death in the literature are numerous, 
although it is difficult to correlate the levels of expression of the ribosomal proteins to those seen 
at a physiological level. The involvement of ribosomal proteins in apoptosis is further evident in 
34 
 
their interaction with Mdm2, an ubiquitin ligase that maintains P53 levels under normal cellular 
conditions by binding and inactivating P53 (as discussed in section 1.2.3). To date, several RPs, 
including RPL11
111
, RPL23
112
 and RPL5
113
, have been found to activate p53 through their 
interactions with MDM2. 
Although cellular events associated with changes in ribosomal protein expression have 
been identified, it is not known what occurs to the ribosomal proteins following 
chemotherapeutic treatment. Earlier research involving doxorubicin treatment of Jurkat cells 
showed that ribosomes are structurally altered in apoptotic cells following the inactivation of 
protein synthesis
158
. Nishisda et al. have also shown that degradation of 3 ribosomal proteins 
following treatment was partially abrogated using a Z-VAD FMK caspase inhibitor.  
Based on preliminary research involving ribosomal proteins, there is reason to believe 
that chemotherapeutic induction of apoptosis/cell death of cancer cells would alter the expression 
of ribosomal proteins. It is unknown whether changes in ribosomal protein composition occur 
upon chemotherapy treatment that would contribute to cell death, possibly by apoptosis. There is 
a lack of evidence in the literature exploring the effects of chemotherapy agents on ribosome 
composition and structure, which may in turn, activate apoptotic and other cell death pathways. 
Of particular interest as well, given the implications of rRNA disruption to chemotherapy 
action
126
, is the effect of chemotherapy and ribosomal protein expression changes on rRNA 
cleavage. If there are any changes in the expression of ribosomal protein and/or it association 
with the ribosome, this could lead to changes in the ribosome structure and/or accessibility of 
certain RNases to the backbone rRNA.  Further investigations into ribosomal protein changes 
following chemotherapeutic treatment could potentially shed light on: a) rRNA disruption and 
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the underlying mechanisms, b) links to apoptotic cell death and c) determine whether changes in 
ribosome protein composition temporally precede rRNA integrity changes 
 
1.6 Hypothesis and research aims  
Based on previous findings, investigating the alteration of ribosome structure following 
chemotherapeutic treatment may provide insight into the mechanism of rRNA disruption and/or 
the cell death pathways elicited shortly after drug exposure. Here, we hypothesize that 
chemotherapeutic treatment (DXL) of A2780 ovarian carcinoma cells will result in changes in 
ribosome composition, both rRNA and ribosomal protein; while we expect a lack of change in 
resistant cells. We further hypothesize that chemotherapy treatment results in the loss of 
ribosomal proteins, which precedes RNA disruption, possibly by permitting access to the 
underlying rRNAs by RNA-degrading RNases.  Finally, chemotherapy-dependent rRNA 
degradation will be lower in assembled ribosomes than in nuclei containing rRNAs that have yet 
to be assembled into ribosomes (greater access to RNases)  To investigate this hypothesis, 5 aims 
have been proposed. 
 
 Aim A) To purify ribosomes from control and DXL-treated ovarian tumour cells 
 Aim b) To identify differences in the composition of purified ribosomes between 
control and DXL-treated cells (rRNA and protein) at various times after DXL 
administration. 
 Aim c) To assess whether ribosome composition is unaltered in ovarian tumour cells 
resistant to DXL.   
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 Aim d) To assess whether ribosomal proteins are lost from ribosomes prior to rRNA 
degradation (RNA disruption) 
 Aim e) To determine whether rRNA degradation (RNA disruption) is lower in 
assembled ribosomes than in nuclei containing fresh rRNA transcripts that have not yet 
been assembled into ribosomes  
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2.0 Materials and Methods 
2.1 Cell lines and cell culture 
The A2780 ovarian carcinoma epithelial cell line was used as an in vitro ovarian cancer 
model in this study. The A2780 cell line was purchased from the European Collection of Cell 
Cultures (ECACC, Salisbury, UK) and maintained in RPMI-1640 medium with 2mM Glutamine, 
which contained 10% fetal bovine serum (FBS) (Gibco, ThermoFisher, Canada), and 1% 
Penicillin (10,000 U/ml)/Streptomycin (10,000 μg/ml) solution (HyClone, South Logan, Utah, 
US) to a final concentration of 100 U/mL penicillin and 100 μg/ml streptomycin. The A2780 
ovarian cancer cell line is likely of the endometrioid subtype
159
. During this study the DXL 
resistant A2780 cell line (A2780DXL) was used as an in vitro model of DXL-resistant ovarian 
cancer. The A2780DXL cell line was generated by selecting A2780 cells for survival in 
increasing doses of DXL as described by Armstrong et al.
12
, using the method of Guo et al.
160
. 
Briefly, the selection began at a dose 1000x below the IC50 for DXL and doses were repeatedly 
increased 3-fold, 1.5-fold and 1.25-fold, with retention of the culture of cell surviving the 
maximum of these dose escalations. This process was continued until a culture of cells was 
obtained containing the maximally tolerated dose of DXL. For the A2780DXL cells used in this 
study, resistance to DXL was maintained by adding 4.05 × 10
-7 
M DXL to the medium weekly. 
All cell lines, including drug resistant cell lines, were cultured in Corning T75 cm
2 
vented tissue 
culture flasks (Corning, New York, United States) and incubated in a water jacketed CO2 
incubator set at 37ºC with 5% CO2. Cell lines were allowed to reach 70-90% confluency, as 
determined by microscopy before undergoing sub-culturing. 
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2.2 Chemotherapy agents and drug treatment 
DXL (Hospira Healthcare Corporation, Saint-Laurent, Québec) was used to induce RNA 
disruption in the A2780 cell line, as was previously described by Narendrula et al.
126
. The drug 
was diluted to the desired concentration in complete media and cells were treated for time 
periods ranging from 12 to 72 hours. The DXL concentration used was based on previous drug 
treatment experiments using the A2780 cell line, during which RNA disruption was observed. A 
concentration of 0.2μM DXL was found to induce maximal RNA disruption126. Unused DXL  
not administered to patients was graciously donated by the pharmacy services at the Northeast 
Cancer Centre at Health Sciences North (Sudbury, Ontario) to Dr. Amadeo Parissenti`s research 
group. DXL was stored in 1mL glass vials at 4ºC and was used within 1 month, as recommended 
by the supplier. For drug dilutions, drug was serially diluted in 15 mL centrifuge tubes in pre-
calculated molar concentrations according to the cell line and its degree of resistance. 
 
2.3 Ribosomal purification – differential centrifugation 
To purify ribosomes, a differential centrifugation technique along with sucrose cushion 
centrifugation to sediment undesired cellular organelles and preferentially pellet intact ribosomal 
species was used
161
. All solutions used were made with diethylpyrocarbonate (DEPC) treated 
ultra-pure deionized water in order to prevent RNA degradation. Cells were plated in T75 tissue 
culture flasks and allowed to grow to approximately 90% confluence. After 3 washes with 15mL 
of cold phosphate-buffered saline (PBS) ( pH 7.4), cells were scraped into 10 mL of cold PBS 
and harvested by centrifugation at 4
o
C for 5 min at 500 x g; the supernatant was aspirated and 
discarded. Cells were re-suspended in cold Buffer A (250 mM sucrose, 250 mM KCl, 5 mM 
39 
 
MgCl2, 50 mM Tris·HCl, pH 7.4) in such a fashion that the volume of Buffer A was 3 times the 
volume of the cell pellet. Cells were lysed by adding a gentle detergent solution of 10% 
octylphenoxypolyethoxyethanol (also known as IGEPAL CA-630), at 4°C to a final 
concentration of 0.7% (v/v). HALT protease and phosphatase inhibitor (Thermo Scientific, 
Rockford, IL, USA) with sodium fluoride (50 mM), sodium orthovanadate (0.2 mM) was added 
at this point to prevent further modification of proteins along with RNAseOUT (Thermo 
Scientific, Rockford, IL, USA), a recombinant ribonuclease inhibitor. After a 15 minute 
incubation period on ice (pipetting the solution twice during the incubation time to ensure proper 
homogenization of cells) the cell lysate was centrifuged for 10 min at 750 x g, 4°C to pellet 
nuclei. The remaining cytoplasmic fraction, i.e. the supernatant, was then decanted and further 
centrifuged for 10 min at 12,500 x g, at 4°C, to pellet the mitochondria. After decanting and 
separating the mitochondrial pellet, the remaining post-mitochondrial fraction was retained as it 
contains the ribosomes. Next, a 4 M KCl solution was slowly added to the post-mitochondrial 
fraction to ensure a final concentration of 0.5 M KCl. This concentration of KCl is necessary to 
ensure the stringent purification of ribosomes devoid of unnecessary contaminating organelles 
and proteins. 
One mL of sucrose cushion (1 M sucrose, 0.5 M KCl, 5 mM MgCl2, 50 mM Tris·HCl pH 
7.4) was then layered into the bottom of a 3 ml polycarbonate centrifuge tube. The KCl-adjusted 
post-mitochondrial fraction was carefully layered above the sucrose cushion and the centrifuge 
tubes accurately balanced to within 0.01 g using Buffer B (250 mM sucrose, 0.5 M KCl, 5mM 
MgCl2, 50 mM Tris·HCl, pH 7.4). The tubes were centrifuged for 2 hours at 250,000 x g, 4°C. 
Following centrifugation, the supernatant was discarded and the dense ribosomal pellet was very 
gently rinsed, twice, by adding 200 μL of cold RNase free water and removing it immediately 
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without disturbing the pellet. After washing, the ribosomes were re-suspended with three 
subsequent additions of 100 μL of Buffer C (25 mM KCl, 5 mM MgCl2, 50 mM Tris·HCl, pH 
7.4) and stored at -80°C.  
 
2.4 Ribosomal Protein purification and quantification 
The ribosomal purification protocol was followed by the addition of 0.7 volumes of 
absolute ethanol to the purified ribosomes in aqueous suspension. The ribosomes precipitated 
immediately, and the suspension was centrifuged at 8,000 x g for 10 minutes to pellet the 
ribosomal subunits. The supernatant was removed and the ribosomes were re-suspended in 250 
µL of homogenization buffer with no sucrose, followed by the addition of 25 µL of 1 M MgCl2 
and 550 µL of glacial acetic acid with gentle mixing. Following a 45 minute incubation period, 
the precipitated RNA from the ribosomes was removed by centrifugation at 10,000 x g for 10 
minutes. The supernatant was removed and placed in another tube containing 4 volumes of 
acetone. The ribosomal proteins immediately precipitated, but the suspension was placed in the 
freezer at –20°C for 2 hours to facilitate complete precipitation of the proteins. The mixture was 
centrifuged at 10,000 x g for 10 minutes to pellet the proteins. The proteins were washed by the 
addition of 1 mL of acetone and centrifuged again. This wash step was repeated once. Proteins 
were solubilized in distilled Millipore water. The protein concentration for the ribosomal protein 
solution and the different organelle fractions (monitored as a measure of quality control) were 
determined using the Pierce BCA Protein Assay Kit (Pierce, Rockford, IL, USA). 
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2.5 1D SDS-PAGE gels  
For each ribosomal protein and cellular fraction preparation, 10 μg of proteins in 2× 
electrophoretic sample buffer (containing 1% DTT, 1M Tris·HCl and .025% Bromophenol blue) 
were heated at 100°C for 5 mins and resolved on 12.5% SDS-PAGE gels for 1.5-2 hours at 35 
mV using the BioRad Protein Mini II cell (Hercules, California, United States). Following 
electrophoresis, gels were fixed using a 25% Isopropanol and 10% acetic acid solution for 1.5 
hours. After fixing, gels were stained overnight in a 10% acetic acid and .0006% Coomassie 
Blue G-250 solution and de-stained as necessary with 10% acetic acid.  
 
2.6 Immunoblotting 
Protein samples were first loaded and run onto a 12.5% polyacrylamide gel as described 
in the ‘‘1D SDS PAGE’’ section above; however, the fixing and staining steps were left out. 
Proteins from the gel were transferred onto BioTrace PVDF membranes (Life Sciences, 
Pensacola, FL, USA) using a BioRad electrophoretic transfer unit. Following electrophoretic 
transfer, the membranes were blocked with a 5% milk solution in 1× TNE buffer (50mM Tris, 
140mM NaCl and 5mM EDTA) containing 0.1% Tween-20 (FisherBiotech, Thermo Fisher 
Scientific Inc., Waltham, MA, USA) for 1 hour. The primary antibody was diluted in a 5% milk 
solution in 1x TNE buffer and incubated with the membrane on a rocker overnight at 4°C. After 
washing the membrane for 3× 20 min in 1× TNE, the membrane was incubated with secondary 
antibody diluted in 5% milk solution in 1x TNE for 1 hour at room temperature. Following 
treatment with the secondary antibody, membranes were washed for 3× 20 min in 1× TNE 
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before the proteins were visualized using the enhanced chemiluminescence (ECL) method using 
peroxidase
162
.  
In order to assess the purity of the ribosome preparations and other organelle fractions, all 
preparations and fractions were examined in immunoblotting experiments for expression of 
specific proteins known to reside in specific organelles. Antibodies to proteins in the 
endoplasmic reticulum, mitochondria, nucleus, and ribosomes were used in this assessment 
(ERP72, VDAC, H2AX, and RPL7a, respectively). The same membrane was reblotted with 
primary antibodies against RPL7a, RPL3, RPL4 and RPSA during ribosomal protein 
experiments. The antibodies for VDAC (4866) and RPL7a (E109) were obtained from Cell 
Signaling Technology, Inc. (New England Biolabs, Ltd., Whitby, ON, CA). Primary antibody for 
RPL3 (sc-86828) was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). 
The goat anti-rabbit (sc-2030) IgG-HRP and goat anti-mouse (sc-2005) IgG-HRP secondary 
antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The 
primary antibodies for H2AX (pS139) and ERP72 (610970) were obtained from BD Biosciences 
(Franklin Lakes, New Jersey, USA) whilst the primary antibodies for RPL4 (11302-1-AP) and 
RPSA (14533-1-AP) were purchased from Proteintech Group Inc. (VWR International, 
Mississauga, Ontario, Canada). 
 
2.7 Two dimensional gel electrophoresis 
Ribosomal proteins were further separated and analyzed by 2D gel electrophoresis 
(2DGE). A dried ribosomal protein pellet (dried using a Savant SpeedVac Concentrator, Thermo 
Scientific, Rockford, IL, USA) containing 50-100μg of ribosomal protein was re-suspended in 
100 μL Isoelectric-focusing (IEF) rehydration buffer containing 7 M Urea, 2 M Thiourea, 4% 
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CHAPS, 1% ampholyte (IPG Buffer pH 7-11 NL, GE Healthcare Life Sciences, Mississauga, 
ON, Canada), 0.001% Bromophenol blue, and 1.5% De-streaking agent (2-hydroxyethyl-
disulfide) (Sigma Aldrich, Oakville, ON, Canada). After 2 hours at room temperature to allow 
full dissolution of the proteins, the protein solution was placed on a paper bridge (3 cm x 0.4 cm) 
and was actively loaded at 500V for 16 hours into a previously hydrated 18cm Immobiline 
isoelectric focusing dry strip (pH 6-11; GE Healthcare Life Sciences, Mississauga, ON, Canada) 
using anodic paper bridge loading
163
. Next, the IEF strip was focused for a total of 35 kVh using 
water-soaked paper wicks on both anodic and cathodic sides of the focusing tray. Following 
focusing, the strips were equilibrated using an equilibration buffer (6 M Urea, 0.375 M Tris HCl 
pH 8.8, 2% SDS, 20% glycerol) in two washing steps. The first wash step consisted of a 20 min 
wash with the equilibration buffer containing 130 mM DTT to reduce the proteins while the 
second wash step consisted of a 20 min wash with a buffer containing 135 mM Iodoacetamide to 
alkylate the proteins. The strip was then trimmed to a length of 11 cm to accommodate an 11 cm 
wide well in an 8-16% gradient acrylamide gel, buffered with Tris-HCl to pH 8.6. The gel also 
contained a single lane beside the 11 cm well, for loading size markers (Biorad, Hercules, 
California, United States). After insertion into the 11 cm IEF strip well, the IEF strip was 
overlaid with overlay agarose consisting of 0.75% agarose and 0.003% Bromophenol blue with 
1x TGS (25mM Tris, 192mM glycine and 0.1% SDS) buffer before being run at 200v for 1 hour. 
Before being imaged, the 2D gel was stained with Flamingo fluorescent stain (BioRad, Hercules, 
California, United States) according to the manufacturer`s protocol. 
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2.8 RNA extraction 
RNA was extracted from cells, purified ribosomes, and subcellular organelle fractions 
using the miRNeasy
TM
 Micro Kit from Qiagen Laboratories (Mississauga, ON, Canada). Briefly, 
A2780 cells, purified ribosomes and the subcellular fractions were lysed using 700µL of QIAzol 
lysis buffer, a monophasic solution of phenol and guanidine thiocyanate, designed to lyse tissues 
and inhibit RNases. The lysed cells were scraped and collected from the cell wells using sterile 
cell scrapers (Fisher Scientific, Ottawa, ON) and all samples were handled using sterile-RNase 
free centrifuge tubes (Fisher Scientific, Ottawa, ON). Samples were then disrupted and 
homogenized in the QIAzol Lysis Reagent by passing the homogenate through a 20 gauge needle 
5-10 times. After addition of chloroform, the homogenate was separated into aqueous and 
organic phases by centrifugation. The RNA partitions to the upper, aqueous phase while DNA 
and proteins partition to the interphase or  the lower, organic phase
164
. RNA was precipitated 
from the aqueous phase by addition of anhydrous ethanol. The RNA was then bound to a silica-
based RNeasy spin column and washed with proprietary buffers (RPE and RWT buffers) before 
being eluted in 50 µL of RNase-free water. Samples were aliquoted in 5 µL volumes before 
being stored at -80ºC until further analysis was performed. 
 
2.9 RNA quality analysis in purified ribosomes and nuclei 
The integrity of extracted total RNA samples was analyzed using capillary gel 
electrophoresis. Specifically, RNA samples were loaded onto an RNA Nano Chip (Agilent 
Technologies, Santa Clara, CA) as directed by the manufacturer’s protocol and analyzed with 
Agilent 2100 Bioanalyzer (2100 Expert software, Agilent Technologies, Santa Clara, CA). This 
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technology utilizes microfluidics coupled with capillary electrophoresis to generate an 
electropherogram. This electropherogram displays/plots the migration time in seconds of the 
extracted RNAs and RNA fragments, which the software converts to nucleotide (Nt) size using a 
set algorithm and specific masses of RNA reference standards. The fluorescence intensity of the 
various RNA peaks in fluorescence units (FU), can then be used to quantify the total mass of 
RNA present. The electropherogram displays two distinctive peaks that correspond to the 28S 
and 18S eukaryotic rRNA subunits. The software includes an algorithm that also calculates and 
analyzes all significant electrophoretic traces of RNA fragments other than the 28S and 18S 
ribosomal subunits. Therefore, the integrity of the RNA sample can be measured using a 
proprietary RIN or ‘‘RNA Integrity Number’’ value.  
 
2.10 Statistical Analyses 
During this study, the significance of differences in data sets was assessed using a 
Student t-test, after application of the F-test to determine if the samples within an experiment 
contained significantly different amounts of variation. A P value of < 0.05 was considered to be 
statistically significant. Statistical analyses were performed using Microsoft Excel or GraphPad 
Prism 5 software. 
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3.0 Results  
3.1 1D SDS-PAGE of Protein fractions obtained during ribosomal purification  
3.1.1 1D SDS-PAGE of Protein fractions obtained during Purification of Monosomes  
There are different sub-populations of mature ribosomes found within the cytoplasm of 
eukaryotic cells.  These include monosomes (a single ribosome translating a single mRNA 
strand) and polysomes (several actively translating ribosomes per a single mRNA strand). Both 
the monosomal and polysomal populations of ribosomes were investigated in this study. In order 
to assess the efficacy of the differential centrifugation protocol used to purify intact ribosomes 
(monosomes) from confluent A2780 cells (see Figure 1), a one dimensional SDS-PAGE gel of 
the subcellular protein fractions obtained during the purification of ribosomes was run. By 
observing the profile obtained from each protein fraction, we were able to assess whether or not 
the outlined protocol facilitates purification of intact ribosomal subunits. The total cell extract of 
A2780 cells had a large amount of protein that spanned a wide range of molecular sizes, as seen 
in Figure 2. As we would expect, the nuclear protein fraction contained a variety of proteins, 
with the histones being quite evident at approximately 15 kDa. The ribosomal protein fraction 
was indicative of purified ribosomes, since the protein banding pattern compared nicely to that 
obtained by Belin et al
161
. We also saw a sudden and drastic change in the quantity and variety of 
molecular weights present in the purified ribosomal proteins in comparison to the other lanes in 
the gel in Figure 2. The sharp, high intensities and distinct grouping of the proteins identified that 
there were fewer proteins compared to the other purification fractions, yet of a higher yield. The 
79 ribosomal proteins in human cell lines display molecular weights ranging from approximately 
5-50 kDa
165
. The range of molecular weights of the proteins in the ribosomal fraction that can be 
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seen in Figure 2 were as expected for a human ribosomal fraction. The protocol established by 
Bélin et al.
161
, from which this protocol was adapted, used a 1D SDS-PAGE banding pattern as 
the sole criteria for measuring purity of the ribosomal fraction. The ribosomal protein profile 
presented in the original protocol bears high similarity to the Coomassie stained ribosomal 
profile we obtained (Figure 2), particularly the range of the molecular weights of the proteins. 
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Figure 1 - Workflow of the differential centrifugation protocol for purification of intact 
ribosomes, based on the protocol established by S. Bélin et al.  
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Figure 2 – Protein profiles of fractions obtained during ribosome purification. Samples were 
run in a 12.5% acrylamide gel and stained with Coomassie blue. 10 μg of protein were loaded 
per lane, as determined using the BCA assay. The profile observed above for the ribosomal 
fraction was indicative of pure ribosomes, as ribosomal proteins have reported molecular 
weights spanning from 5-50 KDa.  The asterisk denotes histone proteins at 15kDa. The gel 
image is representative of three independently conducted experiments. 
* 
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3.1.2 1D SDS-PAGE of protein fractions obtained during purification of polysomes  
As shown in Figure 3, the overall pattern obtained for the protein fractions during the 
purification of polysomes was similar to the monosomal pattern in Figure 2. However, upon 
scrutiny, there was some evident discrepancies. In Figure 3, the total cell extract for the 
preparation of polysomes appeared to have an enrichment in the histones, which can be found 
around 15 kDa. However, it is probable that it is also profilin, an actin-binding protein involved 
in the dynamic turnover and restructuring of the actin cytoskeleton
166
. Moreover, the polysome 
preparations contained a large amount of protein with molecular weights above 70 kDa, which is 
out of the molecular weight range of human ribosomal proteins. Due to the fact that the KCl 
concentration must be altered (lowered to 0.025 M) for all solutions in the isolation of 
polysomes, this changes the stringency of the purification protocol and allows for a larger 
amount of protein to be  co-sedimented with the ribosomal pellet during centrifugation
161
. Due to 
this fact, further analyses with DXL treatment will use the monosomal fractionation of ribosomes 
because the monosomal fractions have reduced levels of higher molecular weight proteins. 
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Ladder           
Total Cell 
Extract       
Nuclear 
Fraction 
Polysome  
Fraction 
Post Mito 
Fraction KDa 
50 
20 
100 
75 
37 
25 
10 
150 
250 
15 
Figure 3 – Protein profiles of fractions obtained during polysome purification. Samples were 
run on a 12.5% acrylamide gel and stained with Coomassie blue. 10μg of protein were loaded 
per lane, as determined by the BCA assay. The profile observed above for the ribosomal 
fraction is indicative of pure ribosomes (ribosomal proteins have molecular weights spanning 
from 7- 67 kDa). Due to a decrease in the KCl concentration to 0.025M in buffers to 
accommodate for polysome purification, there is more noticeable contamination of higher 
molecular weight species. The gel image is representative of three independently conducted 
experiments. 
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3.2 Western blot analysis of protein fractions obtained during purification of ribosomes 
As the results of Figure 2 indicate, the ribosomal protein fraction obtained after 
purification of intact ribosomes from A2780 cells demonstrated significant enrichment of 
ribosomal proteins. To ensure that there was no appreciable contamination of the ribosomal 
protein fraction with proteins from other cellular organelles, a series of western blots were 
conducted using antibodies to proteins known to be expressed abundantly in the ribosome, 
nucleus, mitochondria and endoplasmic reticulum. Antibodies for RPL7a (ribosomal protein 7 of 
the eukaryotic 60S ribosome subunit), H2Ax (nuclear histone protein), VDAC (mitochondrial-
specific voltage dependent anion channel) and ERP72 (endoplasmic reticulum protein disulfide 
isomerase) were used in this assessment. In Figure 4, 10 μg of proteins from each cellular 
fraction were run on a SDS-PAGE denaturing gel, transferred to a PVDF membrane and blotted 
with above antibodies. We observed a clear enrichment for RPL7a in the ribosomal fraction (RB) 
in comparison to all other fractions. H2Ax, VDAC and ERP72 were not present in the ribosomal 
fraction, indicating the efficacy of the protocol for obtaining ribosomal particles devoid of 
contaminating organelles. 
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Figure 4 -Western blots of organelle fractions obtained during the differential centrifugation 
protocol for isolation of ribosomes. TC- Total cell extract, NF- Nuclear fraction, MT- 
mitochondrial fraction, PMT- Post mitochondrial fraction, RB- Ribosomal fraction. RPL7a- 
ribosomal protein of the eukaryotic 60s ribosome subunit, H2Ax- nuclear histone protein, 
VDAC- voltage dependent anion channel (mitochondrial specific), ERP72- endoplasmic 
reticulum protein disulfide isomerase. Samples were run on a 12.5% acrylamide gel with 10 
μg of protein loaded per lane, as determined per BCA assay. The gel image is representative 
of three independently conducted experiments. 
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3.3 Capillary electrophoresis of rRNA isolated from monosomal purification 
To ensure that intact ribosomes were being pelleted during the differential centrifugation 
protocol, rRNA isolated from the ribosomal fraction was also monitored by capillary 
electrophoresis on an Agilent 2100 bioanalyzer. Following the ribosomal purification, RNA was 
extracted from the various fractions using a Qiagen miRNeasy purification column and kit. The 
total cellular RNA obtained from confluent A2780 cells, is shown in Figure 5. The RNA 
displayed the typical strong 28S and 18S rRNA bands seen in high quality total cellular RNA. 
The nuclear fraction contained a variety of other RNA species above the typical 28S and 18S 
rRNA bands, which could speculatively be the primary rRNA transcripts prior to or partially 
through splicing. The monosomal fraction displayed strong 28S and 18S rRNA bands; however, 
there were distinct and reproducible bands that appeared with the isolation of rRNA from 
purified ribosomes. We believe these bands are indicative of rRNA fragments that occurring 
during regular ribosomal turnover, most likely ribophagy
167
. Although precautions were taken to 
prevent RNase contamination, it is possible the bands mentioned are due to RNase degradation   
All solutions used in the extraction process were DEPC treated and RNAseOUT (Thermo 
Scientific, Rockford, IL, USA), a recombinant ribonuclease inhibitor, was also added to the 
ribosomal preparations. The analysis of total cellular RNA by capillary electrophoresis informs 
us that intact rRNA was purified from monosomes, along with the purified proteins. 
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Figure 5 – Capillary gel electrophoresis of fractions obtained during the purification of 
monosomes. A2780 cells were grown to confluence and the monosomal population of 
ribosomes was purified as described previously. RNA was extracted from various fractions 
during monosome purification using Qiagen miRNeasy kits and the RNA in the fractions was 
resolved using capillary gel electrophoresis. RNA was isolated from the following fractions: 
TC (Total Cell Fraction), NF (Nuclear Fraction), PMT (Post Mitochondrial Fraction) and 
Mon (Monosomal Fraction). A) Virtual gel B) Corresponding electropherograms. The gel 
image is representative of three independently performed experiments. 
A) B) 
56 
 
3.4 Capillary electrophoresis of rRNA isolated from polysomes 
As described previously, isolation of polysomes requires the lowering of the KCl 
concentration in various buffers to preferentially pellet polysomes
168
. To ensure that intact 
ribosomes were being pelleted during the isolation of polysomes, RNA from the various 
fractions were isolated using Qiagen miRNeasy kits and component RNAs monitored by 
capillary electrophoresis on an Agilent 2100 bioanalyzer. The total cellular RNA fraction 
obtained from confluent A2780 cells is shown in Figure 6 and displayed the typical strong 28S 
and 18S rRNA bands seen in high quality total cell RNA. Purified polysomes displayed strong 
28S and 18S rRNA bands, but there was an absence of the distinct atypical bands that appeared 
in purified monosome preparations, which may represent rRNA turnover products. The integrity 
of RNA in the isolation of polysomes was facilitated by treating all solutions used in the 
extraction process with DEPC and by adding a recombinant ribonuclease inhibitor, RNAseOUT 
(Thermo Scientific, Rockford, IL, USA), to polysomal preparations. Our data suggests that intact 
rRNA could be purified from isolated monosomes or polysomes, along with their associated 
proteins. 
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Figure 6 - Capillary gel electrophoresis of fractions during the purification of polysomes. 
A2780 cells were grown to confluence and polysomes purified as described previously. 
RNA was then extracted from the various fractions during polysome purification using 
Qiagen miRNeasy kits and the various component RNAs in the fractions resolved by 
capillary gel electrophoresis: TC (Total Cell Fraction), NF (Nuclear Fraction), PMT (Post 
Mitochondrial Fraction) and Pol (Polysomal Fraction). A) Virtual gel B) Corresponding 
electropherograms. The gel image is representative of three independently conducted 
experiments. 
A) B) 
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3.5 Effect of DXL treatment on rRNA from isolated ribosomes 
3.5.1 Effect of 12 hour 0.2 μM DXL exposure on ribosome content and rRNA integrity in 
the various fractions during purification 
After adequate purification of ribosomes from control (untreated) A2780 cells, the effect 
of DXL treatment for various lengths of time on ribosome content and quality was assessed in 
A2780 cells. Previously, our research group had demonstrated, using total cell RNA extracts, 
that RNA disruption bands can be detected as early as 24 hours, with the intensity of cleavage 
products relative to the parent 28S and 18S bands being most significant at 72h
126
. However, 
when RNA was extracted from purified ribosomes, rRNA cleavage products could be detected 
after only 12h of treatment (Figures 7A and 7B). When compared to the A2780 total cell fraction 
that was also exposed to the same treatment conditions, there was a noticeable distinct 
degradation product directly below the 28S rRNA band. This can be seen more clearly in the 
electropherograms present in Figure 7B. Of particular interest, other than this degradation band 
seen in isolated monosomes, the nuclear fraction displayed a striking amount of degradation after 
only 12h of DXL treatment, as seen by the clear absence of any noticeable intact 28S and 18S 
rRNA bands in this fraction. It is likely that the extensive degradation of the nuclear rRNA can 
be attributed to the fact that the nucleus (more specifically the nucleolus) is an early sensor of 
chemotherapeutic treatment
125
. It is also possible that there may be more abundant and/or more 
active RNases in the nuclear fraction upon DXL treatment. 
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Figure 7 - Capillary gel electrophoresis of RNAs from fractions during the purification of 
monosomes from cells treated with 0.2 μM docetaxel for 12 h. A2780 cells were grown to 
confluence and monosomes purified from these cells as described previously, following a 12h  
A) 
B) 
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0.2μM DXL treatment. RNA was extracted from various fractions during the purifications of 
monosomes using Qiagen miRNeasy kits and the component RNAs resolved using capillary 
gel electrophoresis.  The following samples were assessed: CTL (A2780 cell control), TC 
(12h DXL treated Total Cell Fraction), NF (12h DXL treated Nuclear Fraction), Mito (12h 
DXL treated mitochondrial fraction), PMT (12h DXL treated Post Mitochondrial Fraction) 
and 12h-RB (12h DXL treated Ribosomal Fraction). A) Virtual gel B) Corresponding 
electropherograms. The asterisk denotes rRNA disruption products. The gel image is 
representative of a three independent experiments. 
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3.5.2 Effect of 24 hour 0.2 μM DXL exposure on ribosomes and fractions during 
purification 
By 24h of DXL treatment, it became evident that rRNA was cleaved in an orderly 
fashion, in the monosomal (mon), total cell (TC) and ribosomal (RB) fractions (Figure 8A). In 
Figure 8B, in the electropherogram of RNA isolated from monosomes taken from A2780 cells 
treated with 0.2 μM DXL for 24 h, it can be seen that there is 1 strong degradation band below 
the 28S rRNA, along with several slightly weaker degradation bands below the 18S rRNA. As 
has been previously reported by Narendrula et al.
126
, the total cell fraction also began to show 
distinct RNA disruption bands after 24h DXL treatment. In agreement with the observation made 
for cells treated with DXL for 12h, the nuclear fraction (NF) was extensively degraded (Figure 
8A and B), even more so than that at the 12h time point; there was only a very weak 28S rRNA 
band. 
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Figure 8 - RNA profiles for fractions taken from A2780 cells after treatment with 0.2μM 
docetaxel for 24 h. RNA was extracted using Qiagen miRNeasy kits and subsequently 
assessed by capillary gel electrophoresis on an Agilent 2100 bioanalyzer.  The following 
fractions were assessed: TC (Total Cell Fraction), NF (Nuclear Fraction), Mito 
(mitochondrial fraction), PMT (Post Mitochondrial Fraction) and 24h-RB (Ribosomal 
Fraction). A) Virtual gel B) Corresponding electropherograms. Asterisk denotes degradation 
rRNA disruption products. The gel image is representative of three independently conducted 
experiments. *Note: the shifted PMT fraction is due to an error in the bioanalyzer software 
due to the degraded nature of the drug treated sample. 
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3.5.3 Effect of 48 hour 0.2 μM DXL exposure on ribosomes and fractions during 
purification 
In Figure 9, treatment of A2780 with DXL for 48 h resulted in extensive RNA 
degradation in all of the fractions examined. Although the total cell extract displayed distinct 
degradation bands that were greater in intensity that the 28S and 18S rRNAs, the amount of 
degradation was greater in the purified monosomes. The 48h monosomal fraction also displayed 
elevated amounts of distinct reproducible rRNA degradation bands. Compared to the results in 
Figures 7 and 8, the nuclear fraction demonstrated very striking rRNA degradation, including a 
complete absence of both the 28S and 18S rRNA bands. 
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Figure 9 - Capillary gel electrophoresis of RNA isolated from cellular fractions during the 
isolation of monosomes from A2780 cells following treatment with 0.2 μM docetaxel for 48 
h. RNA was then extracted using Qiagen miRNeasy kits and subsequently assessed by 
capillary gel electrophoresis. The following fractions were assessed: TC (Total Cell 
Fraction), NF (Nuclear Fraction), Mito (mitochondrial fraction), PMT (Post Mitochondrial 
Fraction) and 48h-RB (Ribosomal Fraction). A) Virtual gel B) Corresponding 
electropherograms. Asterisk denotes rRNA disruption products. Images are representative of 
three independently conducted experiments. 
B) 
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3.6 Effect of DXL treatment on proteins associated with isolated ribosomes over time 
Once the effect of DXL treatment on rRNA associated with the cellular fractions 
involved in monosome or polysome isolation, the effect of DXL treatment on the protein 
composition of monosomes and polysomes was assessed. Figure 10 displays the protein staining 
pattern for control (untreated) monosomes and polysomes. The protein staining patterns were 
very similar, which was expected. After 12 hours of drug exposure, a global drop in the amount 
of ribosomal protein was observed (noted by the decrease in intensity of staining of proteins in 
the region of 10-70 kDa), with an increase in higher molecular weight proteins. By 24 and 48 hrs 
of drug exposure (Figure 10), there was a significant reduction in ribosomal protein content and 
the results suggest that by 24h of DXL treatment, the majority of ribosomal proteins had been 
“stripped” off of the rRNA backbone of the ribosomes. However, there was a cluster of higher 
molecular weight (40-70kDa) ribosomal proteins that appears to linger, even after 24h or 48h of 
DXL treatment. Although 1 dimensional SDS-PAGE does not allow us to differentiate or 
identify the proteins present, it provides a good starting point for further experimentation.  It also 
provides evidence to strongly suggest that during DXL treatment of A2780 cells, a decrease in 
the ribosomal protein component temporally precedes the degradation of rRNA (RNA 
disruption). 
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Figure 10 – Effects of DXL treatment of ribosomal protein content. A2780 cells were treated 
with docetaxel for various time points, after which monosomes were isolated as described 
above. Proteins from the various cellular fractions during monosome preparation were run on 
12.5% acrylamide gels and stained with Coomassie Blue. 10 μg of protein were loaded per 
lane as determined per BCA assay. Mono (monosomal protein control) , Poly (polysomal 
protein control), 12h (monosomes isolated after 12h DXL treatment), 24h (monosomes 
isolated after 24h DXL treatment), 48h (monosomes isolated after 48h DXL treatment). Red 
arrows denote differences in the polysomal lane. The gel images are representative of three 
independently conducted experiments. 
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3.7 2D gel electrophoresis of ribosomal proteins 
With the 1D SDS-PAGE of ribosomal proteins from DXL-treated A2780 cells 
completed, a two dimensional SDS-PAGE (2DGE) would provide the needed resolution to 
identify which, if any, ribosomal proteins had altered expression with DXL treatment. 2DGE 
separates proteins in the first dimension on an isoelectric focusing strip that separates proteins 
based on their isoelectric point (pI), the pH at which the respective protein’s charge becomes 
neutral due to the nature of the R groups of the amino acids.  The second dimension involves 
standard acrylamide gel electrophoresis. In Figure 11, an optimized resolution of ribosomal 
proteins from control (untreated) A2780 cells is depicted, with a pH gradient from 8.5-11. There 
are numerous proteins that can be seen, with some of them having good resolution. However, 
due to difficulties in the basic range of isoelectric focusing strips, the resolution of a large 
portion of basic proteins in the ribosomal protein preparations was not sufficiently adequate for 
spot-identification software and subsequent mass spectrometric analysis. As well, 
discontinuation of the aforementioned strips (pH range above 10) discontinued this avenue of 
research. 
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Figure 11 - 2D Gel Electrophoresis of purified ribosomal proteins; a superior resolution is 
required for mass-spectrometry. A 6-11 GE Healthcare IPG strip with 1% 6-11 GE 
ampholytes was used. The first dimension was run using de-streak reagent (hydroxyethyl 
disulfide) and CHAPS as a detergent with a total of 40kvhr focusing time. A paper bridge 
loading technique was utilized, as described in Materials and Methods. For the second 
dimension, 8-16% Tris-HCl SDS-PAGE pre-cast gels were used and the IPG strip was run 
at 200v for 55min. A total of 100µg of ribosomal proteins were loaded. Gels were fixed and 
stained with flamingo fluorescent protein stain before being imaged. 
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3.8 2D gel electrophoresis of ribosomal proteins taken from A2780 cells after treatment for 
24h with 0.2uM DXL 
An attempt was made to resolve by 2DGE ribosomal proteins from A2780 cells before 
and after DXL treatment for 24h. A 2D gel of ribosomal proteins from untreated and treated 
A2780 under the most optimal conditions are depicted with Figures 11 and 12, respectively. The 
findings suggest an overall loss of ribosomal proteins, although there are several proteins around 
50 kDa that seem to remain. This supports the results seen in Figure 10, although resolution is 
not sufficient for conclusions to be drawn by mass-spectrometry. 
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Figure 12 - 2D Gel Electrophoresis of purified ribosomal proteins from A2780 cells after 
treatment with 0.2µM docetaxel for 24h. 6-11 GE Healthcare IPG strips with 1% 6-11 GE 
ampholytes were used. The first dimension was run using de-streak reagent (hydroxyethyl 
disulfide) and CHAPS as a detergent, with a total of 40 kVh focusing time. A paper bridge 
loading technique was utilized, as described in Materials and Methods. For the second 
dimension, 8-16% Tris-HCl SDS-PAGE pre-cast gels were used and the IPG strip was run at 
200v for 55min. A total of 100µg of ribosomal proteins were loaded. Gels were fixed and 
stained with flamingo fluorescent protein stain before being imaged. 
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3.9 The effect of DXL treatment on expression levels of select ribosomal proteins in A2780 
cells  
The lack of consistent, high resolution of ribosomal proteins by 2D gel electrophoresis 
required the use of immunoblotting experiments with antibodies for specific high molecular 
weight ribosomal proteins as the means to evaluate changes in ribosomal protein content upon 
DXL treatment. Figure 13A demonstrates changes in the amount of RPL4, RPSA, RPL3 and 
RPL7a in cellular fractions of A2780 cells upon treatment with DXL for 24h. Our findings 
suggested that there were treatment-induced changes in the expression of some of these proteins. 
It was further noted that RPL3 separates into 2 distinguishable isoforms during the glacial acetic 
acid purification step (see section 2.4 for reference). Figure 13B is a bar graph of the expression 
ratio for various ribosomal proteins between treated to untreated A2780 cells. Because different 
subcellular organelle fractions were analyzed, the bands could not be normalized to a standard 
housekeeping gene (GAPH, Actin, etc.). Instead, a ratio of the ribosomal proteins was generated 
by comparing the densitometry values of a specific ribosomal protein in the ribosomal fraction 
versus the total cell fraction, which was then compared between the untreated control and 24h 
DXL treated sample to determine if a significant fold change was observed. This allows us to 
analyze how specific ribosomal proteins in the isolated ribosomal fraction change in response to 
DXL treatment. RPL3 showed a significantly reduced expression upon treatment compared to 
the untreated sample, while RPL7a exhibited a significant increase in expression levels. The 
expression of RPL4 and RPSA did not appear to change significantly in response to DXL 
treatment. 
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Figure 13 – A) Immunoblots documenting the effect of DXL expression on levels of various 
proteins in cellular fractions obtained upon isolation of ribosomes from A2780 cells. RPL4, 
RPL3 iso1, RPL3 iso3, and RPL7a are proteins from the larger 60S ribosomal subunit and 
RPSA is a protein from the smaller 40S ribosomal subunit. These are representative of some 
the highest molecular weight ribosomal proteins and show changes in relative expression after 
drug treatment (TC-total cell, NF-nuclear fraction, MT-mitochondrial, RB-ribosomal)  B) 
Densitometry values for the ribosomal proteins were plotted using GraphPad Prism and 
differences with a p < 0.05 were considered statistically significant (*indicated by an asterisk) 
using a two-tailed t-test. 
A) 
N = 3 
P < 0.05 
B) 
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3.10 The effect of DXL treatment on the levels of select ribosomal proteins in ribosome 
preparations from the A2780DXL cell line 
To investigate if DXL affected ribosomal protein composition in A2780 cells that had 
been selected for DXL resistance, A2780DXL cells were treated with 0.2uM DXL for 24 hours, 
in the same fashion as A2780 cells depicted in Figure 13. The immunoblot results of RPL3, 
RPSA, RPL7a and RPL4 for this experiment are shown in Figure 14A. As mentioned, different 
subcellular organelle fractions were analyzed, which meant that the bands could not be 
normalized to a standard housekeeping gene (GAPH, Actin, etc.). Instead, a ratio of the 
ribosomal proteins was generated by comparing the densitometry values of a specific ribosomal 
protein in the ribosomal fraction versus the total cell fraction, which was then compared between 
the untreated control and 24h DXL treated sample to determine if a significant fold change was 
observed. This allows us to analyze how specific ribosomal proteins in the isolated ribosomal 
fraction change in response to DXL treatment. There were no apparent differences in the level of 
these proteins between DXL-treated and untreated A2780DXL cells. Interestingly, the 
immunoblot for RPL3 did not produce two distinct isoforms as was observed in Figure 13. 
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Figure 14 – A) Immunoblots of ribosomal proteins in ribosomal fractions of: untreated A2780 
cells, untreated A2780DXL cells and A2780DXLcells after treatment with 0.2 µM DXL for 24 
h. RPL4, RPL3 iso1, RPL3 iso3, and RPL7a are proteins from the larger 60S ribosomal subunit 
and RPSA is a protein from the smaller 40S ribosomal subunit. These are representative of some 
of the highest molecular weight ribosomal proteins and show few changes in relative protein 
levels after drug treatment.   B) Densitometry values of the ribosomal proteins were plotted using 
GraphPad Prism and differences with p < 0.05 were considered statistically significant using a 
two-tailed t-test. 
A) 
N = 3 
P < 0.05 
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4.0 Discussion 
The NCIC-CTG-MA.22 clinical trial assessed tumours of patients pre-, mid-, and post 
treatment in order to identify potential biomarkers of response to chemotherapy
151
.  Since only a 
very small percentage of patients with the most abundant subtype of breast cancer (ER+/Her2- 
tumours) receive a survival benefit from chemotherapy 
169
, there is an urgent, unmet need for a 
robust biomarker of response to chemotherapy. This need is particularly urgent, because the vast 
majority of patients receive significant short and long-term toxicities from treatment, including 
cardiotoxicity, thromboemboli, neuropathies, neutropenia, fatigue, and secondary neoplasms
169
.  
Thus, a robust chemoresponse biomarker could possibly enable physicians to identify non-
responders early in treatment, in order to avoid these toxicities and move patients to other 
downstream treatments. 
Although earlier studies had shown that chemotherapy agents interfered with ribosome 
biogenesis
125
, the clinical trial reported by Parissenti et al., was the first study to show that 
treatment with cytotoxic chemotherapy agents such as epirubicin and DXL can induce RNA 
degradation in patient tumors. It has been recently shown by Narendrula et al.
126
 that several 
ovarian and breast cancer cell lines (A2780, CAOV-3, MCF-7, SKBR-3, MDA-MB-231) 
reproducibly demonstrate significant RNA disruption following the application of a variety of 
chemotherapy agents with contrasting mechanisms (DXL, paclitaxel, carboplatin, cisplatin, 
vincristine, irinotecan and etoposide). As was previously stated, DXL was shown to be one of the 
most reproducible and robust agents to induce rRNA degradation in this study
126
. This suggests 
that many chemotherapy agents, despite their distinct mechanisms, ultimately promote the 
degradation of rRNA. If so, then this could reliably be used as a measure of response to 
chemotherapy in cancer cells. 
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However, the mechanism(s) by which these chemotherapy agents induce RNA disruption 
in vitro and in vivo is unknown.  We thus decided to investigate how chemotherapy treatment 
affects ribosome composition, including ribosomal protein content. We hoped that this would 
provide beneficial and new insight into the process and mechanisms of chemotherapy-induced 
RNA disruption. The study of ribosomal proteins following chemotherapy treatment required the 
purification of intact ribosomes from the cytoplasm of tumour cells. This would also allow us to 
monitor the integrity of RNA in ribosomes only, along with the associated ribosomal proteins.  
Consequently, the objectives of this study were to: a) assess the feasibility of purifying 
ribosomes from control and chemotherapy treated A2780 ovarian cancer cells; b) identify 
differences in the composition of purified ribosomes between control and chemotherapy-treated 
cells (rRNA and protein); c) to determine whether any protein composition changes that are 
present in the drug-sensitive A2780 cells would be absent in the DXL resistant A2780DXL cell 
line; d) to assess whether ribosomal proteins are lost from ribosomes prior to rRNA degradation 
(RNA disruption); and e) to determine whether rRNA degradation (RNA disruption) is lower in 
assembled ribosomes than in nuclei containing fresh rRNA transcripts that have not yet been 
assembled into ribosomes  
 
4.1 Evaluation of the purification of ribosomes from A2780 cells using differential 
centrifugation: 1D SDS PAGE and immunoblotting of organelle markers 
In order to evaluate the effectiveness of the differential centrifugation protocol employed 
to purify intact translating ribosomes from the cytoplasm of A2780 ovarian cancer cells, 1D  
acrylamide gel was used to monitor the expression of proteins in the fractions obtained during 
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ribosome purification. The expression of the resolved proteins on the acrylamide gel was 
assessed by staining with Coomassie blue
161
. Figure 2 demonstrates the typical protein profiles 
that were obtained during the purification of ribosomes. Fractions included a total cell extract, 
the nuclear fraction, the post mitochondrial fraction and the ribosome fraction, respectively. It is 
important to remember that although this protocol does create a nuclear and mitochondrial 
fraction, these fractions are not free of other contaminating organelles. The goal of the process 
was to isolate ribosomes devoid of contaminating organelles.  
The gel in Figure 2, shows that there was a clear enrichment of proteins in the 10-70 kDa 
when going from left to right. The total cell extract, nuclear fraction and post mitochondrial 
fraction contain many different proteins of vastly different molecular sizes. However, the 
ribosomal fraction of protein contains a reduced number of protein bands that increase in 
intensity in the 10-70 kDa range
161
. The banding pattern in the 10-70 kDa range is indicative of a 
clear enrichment of ribosomal proteins.  Although previous studies have used this as an endpoint 
to determine purity of their ribosomal samples, we determined it was necessary to evaluate the 
purity of the ribosomal sample using markers for contamination by subcellular fractions other 
than the ribosome. 
 
4.2 Changes in ribosome protein content in response to DXL 
Ribosomal proteins are not simply participants in the function of protein synthesis, 
several ribosomal proteins have ‘second lives’, displaying extra-ribosomal functions that are not 
dependent  on the ribosome
170
. This tendency of ribosomal proteins to have other functions, can 
be explained by theories postulating the pre-existence of the ribosomal proteins as independent 
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molecules before forming the various sub-units of the ribosome
171
. These proteins are also 
known to affect development, apoptosis and aging when their expression levels have been 
altered
156
. Specifically, it is known that ribosomal protein S3a (RPS3a) plays important roles in 
cell transformation and death. Constitutively or transiently enhanced RPS3a expression can be 
regarded as 'priming' a cell for apoptosis
172
. Therefore, monitoring changes in ribosomal protein 
expression following chemotherapeutic treatment is of interest to investigate the mechanism of 
cell death and ribosomal disruption. 
Figure 10 displays the effect of DXL treatment over time on the protein composition of 
ribosomes in A2780 cells. At 12h of treatment, there was a relative reduction in the ribosomal 
protein content (10-70 kDa) compared to the untreated ribosome fraction and there appeared to 
be some changes in the expression of higher molecular weight proteins. By 24h, the bulk of the 
effect of DXL on ribosomal protein content appeared to take effect. There was a cluster of 
ribosomal proteins around 30-50 kDa that appeared to retain their expression, even with 
prolonged treatment (up to 48h).  It is possible that the retention of these proteins in the ribosome 
structure following drug treatment may provide some mechanistic or functional link to drug 
related cellular effects. However it is also just as likely that the increased amount of positive 
charges in the longer polypeptide chains allows for them to be retained to a greater extent by the 
negative backbone of rRNA. 
The altered ribosomal protein content could very well have a direct effect on a cancer 
cell’s translatome (translated array of proteins by the ribosomes present in a cell); although 
speculative, blocked translational capacity could be a part of the cell death mechanism. Iwawaki 
et al. have shown a direct connection between ER stress, the cessation of translational capacity 
and the induction of rRNA degradation by IRE1
140
. The evidence in this study suggests that ER 
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transmembrane kinase/ribonuclease IRE1beta induces translational repression through 28S 
rRNA cleavage in response to an ER stress response. If the stress persists, there may be sufficient 
degradation of rRNAs to render cells non-viable. It is possible that a similar process may be 
occurring here, explaining the RNA disruption observed. 
Some may argue, however, that as the catalytic peptidyl transferase function is located 
within the 28s rRNA, that this would not affect the ‘translatome’, because ribosomes are just 
blind protein producing machines. Refuting this argument is the fact that RPs are extremely 
basic. The inherent capability of the extremely basic ribosomal proteins (pIs typically above a 
pH of 9 or 10)
165
 is to bind RNA molecules, such that they play a major role in ribosome 
structure. The primary function of RPs, if not to participate directly in translation, is to modulate 
the affinity of the rRNA for an mRNA substrate or to aid in the discrete folding of the rRNA in 
the ribosome to achieve a certain 3D catalytic structure to achieve catalytic activity 
173
. It can 
therefore be argued that differential expression of RPs can alter the translatome by altering the 
fine structure of the ribosome; the same can be said for rRNA modifications. It is also important 
to note that the loss of certain ribosomal proteins would likely expose certain sites in the rRNA 
to cleavage by endogenous RNases, including IRE1 and RNase L as previously mentioned.  This  
would explain the RNA disruption observed. 
 
4.3 rRNA content of A2780 Ribosomes 
Figure 5 displays the capillary gel electrophoresis results for cellular fractions during the 
purification of ribosomes from untreated A2780 cells. All fractions displayed strong, intact 28S 
and 18S rRNAs. Interestingly, what was not expected is that the purified ribosomal fraction 
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(even when DEPC treated solutions and RNAse inhibitors were used) contained reproducible 
‘turnover bands’ in the electropherograms. These rRNA bands most likely had once been part of 
a functioning ribosome or are in the process of being degraded in a mature ribosome. This can 
most likely be attributed to regular cellular turnover of ribosomes, as they are highly monitored 
within the cell even during regular growth
167
. Although these turnover products may seem to 
confuse detection of chemotherapy –induced degradation, they are not very intense and do not 
affect the interpretation of the effects of drug treatment as treatment bands are of a distinctly 
different molecular size and intensity. 
As shown in Figure 6, we observed that purified polysomes demonstrated much fewer 
rRNA turnover products than purified monosomes. However, as it had already been determined 
that the polysome purification (changes in KCl concentration) allowed for a higher amount of 
contamination by other organelle fractions, the monosomal extracts were used for further 
experiments during drug treatment. 
 
4.4 Changes in rRNA integrity in response to DXL 
While DXL-induced degradation of rRNA has previously been observed by our research 
group in A2780 cells, it was unclear whether these rRNA degradation bands stemmed from a 
cytoplasmic population of mature ribosomes or from freshly synthesized ribosomes, rRNA 
and/or rRNA pre-cursors in the nucleus. To address this question, the integrity of the rRNA 
present in various cellular fractions during monosome purification was assessed using the 
Agilent 2100 bioanalyzer.  This was achieved by differential centrifugation; ensuring that only 
the high molecular weight ribosomes were pelleted followed by preparation of RNA from 
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monosomes. Figure 7 displays the effect of a 12 hour 0.2 µM DXL treatment on the integrity of 
rRNA in cellular fractions obtained during the purification of monosomes. The nuclear fraction 
demonstrated significantly aberrant rRNA profiles compared to the untreated control. There were 
degradation bands present in the mitochondrial and post mitochondrial fractions as well, with a 
variety of other RNA bands not usually seen in the total cell extracts. These additional RNA 
species most likely arise from the enrichment of various rRNA fragments not readily apparent in 
the total cellular RNA preparation. Although these fractions have been included to monitor the 
ribosome purification process, no conclusions could be drawn from them because these fractions 
still contained a mixture of cellular organelles. The purified monosomes displayed discrete bands 
appearing below the 28S and 18S rRNAs. Although not as intense as the parental rRNA bands, 
the degradation bands were noticeable in monosomal RNA preparations after 12 hours of drug 
exposure. This was particularly noticeable in the electropherogram of Figure 7B, a phenomenon 
not readily observable in total cell extracts. By 24h of treatment, there were significant disruption 
bands present in the ribosomal fraction, and by 48h of DXL treatment, the intact rRNA bands 
were almost completely absent (Figure 9). Several attempts at purifying ribosomes from 72h 
treated cells were made, but the ribosome degradation was so severe that no intact ribosomes 
could be pelleted upon centrifugation. However, it is noteworthy that in comparison to total cell 
extracts, the disruption products from purified ribosomes: a) can be detected earlier than in total 
cell extracts (as early as 12 hours); and b) are representative of translating cytoplasmic ribosomal 
particles and therefore cannot be detected post 48h of treatment (greater sensitivity).  
Other than the ribosomal fraction undergoing degradation, it is quite important to note 
that the rRNA fraction extracted from the pelleted nuclei of DXL-treated A2780 cells underwent 
extensive degradation. The degradation of the nuclear fraction of rRNA was very extensive even 
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after only 12 hours of DXL treatment (Figure 7). By 24h and especially at 48h of DXL 
treatment, there was no recognizable 28S or 18S in the isolated RNA from the nuclear fraction, 
in Figures 8 and 9 respectively. This quick degradation of rRNA after drug exposure can be 
interpreted as the nuclear, and most likely the nucleolar, fractions undergoing extensive 
degradation/regulation to prevent the further production of ribosomes. Before large disruption 
bands appear in the cytoplasmic (monosomal) fraction of ribosomes, the nascent ribosomes 
(rRNA and pre-rRNA) in the nucleus are extensively degraded after 12h of drug exposure. This 
is added evidence to suggest effective chemotherapeutic treatment of cancer cells targets the 
ribosomes as part of, or as a by-product of the mechanism of cell death
125
. Further research needs 
to be conducted in evaluating how chemotherapy agents may interfere with ribosome biogenesis 
and structure. This avenue shows much promise for advances in treatment, patient care and 
potential cures for specific cancers. 
The most likely candidate to explain the loss of 28S and 18S rRNA and the presence of 
specific rRNA cleavage products is an endogenous RNase. As mentioned, RNAse L and IRE1 
form likely candidates as they have already been implicated with degradation of the 28S rRNA 
following situations of cell stress (IRE1 is activated in situations of ER stress while RNase L is 
activated in a situation of viral infection or detection of dsRNA). Although no mechanism has 
been delineated, we propose that the treatment of cancer cells with chemotherapeutic agents 
elicits similar or identical responses of cell stress (ER stress, nuclear stress, production of foreign 
dsRNA molecules) that activate stress induced RNases, allowing to cleave unprotected regions 
of rRNA. 
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4.5 2DGE: evaluating the effect of DXL treatment on ribosome protein content 
In order to evaluate the changes in expression of a relatively large and complex set of 
proteins, two dimensional gel electrophoresis is an unrivaled molecular biology technique to 
accomplish this task. Mammalian ribosomal proteins have an average molecular weight of 
18,500 Da (the range is 47,280 for L4 to 3,454 for L41). They have an average of 164 amino 
acids (the range is 421 to 25) 
165
. The proteins are very basic; they have an average pI of 11.05 
(the range for pI is 4.07 to 13.46) and contain 22% arginine and lysine amino acid residues
165
. 
The proteins are likely to contain a number of clusters of basic residues. Unfortunately, these 
characteristics of ribosomal proteins make them some of the most difficult to analyze by 
commercially available 2D electrophoresis systems using strip gels or IPG (immobilized pH 
gradients) for the 1
st
 dimension (isoelectric focusing). The pH gradients of IPGs are generated by 
means of buffers that are covalently bound into porous, polyacrylamide gels
174
. While 2-D 
PAGE is an ideal tool for discovery-phase research, not all expressed proteins can be displayed 
in a single gel. Low-abundance proteins, very large and very small proteins, basic, acidic 
proteins, and hydrophobic proteins present their own special challenges for 2-D PAGE. Of noted 
difficulty, IPGs for very basic proteins, with pIs in the pH 8-11 range, may require matrices other 
than polyacrylamide
175
. For reasons that are not clear, proteins with pIs greater than about pH 
10.5 are extremely difficult to focus in IPGs
174
.  
Figures 11 and 12 display the results of optimized 2D gels for proteins extracted from 
ribosomes isolated from untreated and DXL-treatedA2780 cells, respectively. Although a clear 
reduction in ribosome protein content was observed upon DXL treatment, the resolution of the 
2D gels was not sufficient enough to allow for mass spectrometric analysis. A year was devoted 
to optimizing 2D gels for mass spectrometric analysis. The addition of several agents, utilization 
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of several sets of detergents, reducing agents, IPG strips, loading techniques, voltage times and 
intensities, etc. were explored. However, the difficulties in resolving strongly basic proteins in 
2D gels, along with the discontinuation of certain IPG products, lead to inconsistent quality of 
gels, prompting us to abandon the 2DGE approach for evaluating the effects of DXL treatment 
on ribosome protein content. The 2DGE results presented in Figures 11 and 12 cannot identify 
changes in the levels of specific ribosomal proteins in response to DXL treatment. But, they did 
document a large drop in the levels of specific ribosomal proteins, while other proteins exhibited 
increased or little change expression with DXL treatment. This interesting finding corroborates 
the 1D gel results obtained in Figure 10, and warranted subsequent western blotting experiments 
to identify which specific ribosomal proteins were increased/decreased. 
 
4.6 Altered composition of high molecular weight ribosomal proteins in response to DXL 
treatment 
A subset of 4 high molecular weight proteins stemming from both the large and the small 
subunit of the ribosome (RPL3, RPL4, RPL7a and RPSA) were queried for possible changes in 
their levels following DXL treatment. These proteins were chosen as their molecular weights 
matched a series of ribosomal proteins that seemed to have and increased/altered levels. In 
Figure 13B, it is evident that RPL3 showed significantly lower levels in ribosomes isolated for 
DXL-treated cells compared to the untreated cells, while RPL7a exhibited increased levels. 
Although there were some changes in RPL7a and RPL3 levels, the ratios of RPL4 and RPSA 
seem to remain unchanged. This tells us that there is an altered levels of ribosomal proteins 
following DXL treatment. As discussed in section 4.2 of the discussion, it is possible that these 
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changes in ribosomal protein content are part of a cell death mechanism that changes the 
translatome of cancer cells, promoting apoptotic death
156
. 
It is interesting that, of the ribosomal proteins investigated, RPL7a was found to be the 
only protein to increase in content after DXL treatment. Previously, changes in RPL7 expression 
have been linked to changes in the cell cycle and progression to cell death
154
. RPL7 was found to 
contain a basic region leucine zipper (BZIP), characteristic of eukaryotic transcription factors, 
which can bind to and interact with cognate sites on mRNA to inhibit cell free translation of 
distinct mRNAs
176
. Corroborative with previously discussed implication with ribosomal proteins 
and apoptosis, constitutive expression of human ribosomal protein L7 arrests the cell cycle in G1 
and induces apoptosis in Jurkat T-lymphoma cells
154
. Based on this observation in Jurkat cells, it 
is possible that the increase in RPL7a could be a contributing factor to cell death in A2780 cells 
following DXL treatment. Further studies would need to be conducted to explore this potential 
link. 
At this time it is unknown what causes the change in RP levels, as a number of causes 
could provide a valid explanation: selective degradation, loss from the rRNA backbone of the 
ribosome or even cleavage. Because there was a removal/degradation/loss of ribosomal proteins 
from the intact cytoplasmic ribosomes following 24 hour DXL treatment in A2780 cells, it is 
possible that the loss of specific ribosomal proteins could allow or facilitate subsequent selective 
cleavage of the underlying rRNA sequences (as presented in Figures 7-9). At this time it is 
difficult to delineate a definite mechanism, or point to specific ribosomal proteins that may be 
involved. Wen et al. have shown that eIF3f promotes rRNA degradation through direct 
interaction with heterogeneous nuclear ribonucleoprotein (hnRNP) K. Specifically, hnRNP K is 
required for maintaining rRNA stability: under stress conditions, eIF3f dissociates hnRNP K 
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from rRNA, thereby preventing it from protecting rRNA from degradation
177
. It is very likely 
that that the ribosomal proteins protect the RNA in a similar fashion from RNase cleavage. 
We have previously shown that the rRNA of cancer cells was selectively cleaved 
following chemotherapeutic treatment. The results in figure 13 are the first to demonstrate that 
the ribosomal proteins of A2780 ovarian cancer cells also undergo a process of degradation. 
When both of these results are taken into consideration, the hypothesis that ribosomes are a 
target and/or sensor of chemotherapeutic treatment appears compelling. Results of 1D gels of 
ribosomal proteins following treatment (see Figure 10) also tend to suggest that the loss of the 
protein fraction of ribosomes tend to occur at an earlier rate that that of the rRNA. By 12h, very 
noticeable changes with ribosomal protein can be noted in Figure 10; the same of which cannot 
be stated for the rRNA at this time.  Our data and the above findings thus suggest that RP loss 
precedes and facilitates RNA disruption 
rRNA and the disruption products produced following chemotherapy treatment are 
currently being evaluated as a biomarker to monitor the efficacy and predict outcome of the 
chemotherapeutic regimen being utilized, as mentioned in the introduction section. A company 
formed to develop RNA disruption as a biomarker of response to chemotherapy, RNA 
Diagnostics, Inc., and they have developed a proprietary algorithm based diagnostic tool termed 
RDA (RNA Disruption Assay), which is a diagnostic test measuring breast tumor response early 
in chemotherapy treatment
152
. It does so by analyzing the extent of rRNA disruption in patient 
samples. As the research above demonstrates, there is also the possibility that ribosomal proteins 
and their expression/presence within translating ribosomes following chemotherapeutic treatment 
could be used to monitor treatment efficacy of screen for new agents. Human ribosomal proteins 
and their expression and regulation within human tissues are relatively newly studied subjects 
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(especially when it comes to their relation with cancer). There is a lack of research in the field of 
ribosomal proteins and the implication of ribosomes and cancer; and especially how this plays a 
role in the treatment of cancer. 
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5.0 Summary and Future Perspectives 
Although it was known from previous studies in our laboratory that chemotherapeutic 
treatment of cancer cells in vitro caused cleavage of the 28S and 18S rRNAs
126
, it was not known 
whether this occurred in the translating population of cytoplasmic ribosomes and if similar 
changes also occurred in the composition of translating ribosomes, including levels of RPs. We 
have used a highly efficient protocol for the purification of intact ribosomes (monosomes), 
devoid of contamination, as assessed by one dimensional gel electrophoresis, with subsequent 
western blotting for assessment of expression for proteins associated with other cellular 
organelles. RNA and protein preparations from the purified ribosomes were then obtained for 
further analysis. 
We were able to demonstrate that for DXL-treated ovarian tumour cells, the creation of 
cellular fractions for ribosome purification appeared to allow for more sensitive detection of 
rRNA disruption by capillary electrophoresis than a total cellular RNA preparation. Following 
DXL treatment, the rRNA within cytoplasmic ribosomes underwent significant degradation in 
cytoplasmic ribosomes - first noticeable after 12h, but with even greater degradation as time 
progressed to 24 and 48 hours. Interestingly, by 72h of DXL treatment, there were no intact 
ribosomes remaining in the cytosol of A2780 cells. Of particular interest was the nuclear fraction 
of rRNA, which reproducibly showed extensive degradation after only 12 hours of DXL 
exposure. This was interpreted as the rRNA primary transcript and nascent rRNA molecules (yet 
to be incorporated into mature ribosomes with their associated proteins) undergoing extensive 
degradation by RNAses following drug exposure. 
The number and amount of ribosomal proteins from purified ribosomes, as assessed by 
1DGE, decreased after DXL treatment, as early as 12h. By 24h, there was a greater drop in the 
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total ribosomal protein content of purified ribosomes.  In contrast, there appeared to be elevated 
levels of other ribosomal protein, the majority of which had higher molecular weights in 
comparison to the average ribosomal protein. It is difficult to say if the retention of these basic 
proteins was due to their inherent longer length and the resulting increased points of contact with 
the acidic rRNA, or due to other reasons. Further experimentation would need to be conducted to 
determine how the loss of some ribosomal proteins could allow for the cleavage of the 
underlying rRNA sequences by endogenous RNases, which would explain the rRNA cleavage 
patterns observed. 
2D gels of human ribosomal proteins using IPG strips are not advised as means of 
evaluating differences in ribosome content between control and chemotherapy-treated tumour 
cells, as the inherent basic nature of human ribosomal proteins (average pI of 11) causes much 
difficulty in the isoelectric focusing of the proteins. With an insufficient resolution in the 1
st
 
dimension, mass spectrometric analysis becomes impossible due to streaky and unresolved gels 
in the 2D gel. Although it is possible to use this technique to achieve greater resolution of 
ribosomal proteins, these technical issues provide no advantage over classical 1D SDS-PAGE 
The levels of certain proteins in isolated ribosomes were assessed by western blotting 
using untreated and DXL-treated A2780 cells. Of particular interest was RPL7a. While RPL7a 
was shown to increase in relative quantity, some ribosomal proteins had the same relative 
expression to the untreated control and RPS3 decreased significantly. It is possible that these 
changes in ribosomal protein (e.g. RPL7a) could initiate apoptotic cell death, or that these 
decreases in ribosomal protein e.g. (RPS3) could allow for subsequent accessibility of RNases to 
the rRNA structure, producing the rRNA disruption bands observed following chemotherapeutic 
treatment. 
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There is an absence of changes in ribosomal protein content following treatment of the 
resistant cell line with DXL. This can be correlated with an absence of DXL-induced RNA 
disruption in these cells, as reported previously
126
. This strengthens the utility of RNA disruption 
as a chemoresponse biomarker. The rRNA degradation products following chemotherapeutic 
treatment are already being evaluated as a biomarker for positive response to treatment as 
reviewed in Section 1.5.2. It may be possible to also detect changes in ribosomal protein content 
in samples, as a measure of response to chemotherapy treatment. If an alteration in ribosome 
structure (rRNA + protein) is a consequence of cellular exposure to many structurally distinct 
chemotherapy drugs, then it would be extremely beneficial to use agents that demonstrate a 
higher selectivity for cancer cell ribosomes, potentially avoiding unwanted side effects and 
improving patient care. This would also strengthen the argument to monitor ribosome decay 
products as a screen for new potent anti-cancer agents, as there has not been a leap in cancer 
drug discovery in recent years. RNA disruption, as assessed by RDI
TM
 would prove a great 
means of screening chemotherapeutic agents for potential ribosome decay products. Screening 
for changes in ribosomal protein content would also be possible (and made easier if a specific 
ribosomal protein was a known target) by using mass spectrometric analysis of ribosomal protein 
extracts. Furthermore, by altering the levels of ribosomal proteins or targeting the ribosome 
structure directly, it may be possible to more effectively target cancer cells directly, although to 
our knowledge this has yet to be done. Just as disruption of ribosome biogenesis with an 
inhibitor of RNA polymerase I transcription, CX-5461, has shown unexpected, potent, and 
selective effects in killing tumor cells via disruption of nucleolar function
91
,  it may be possible 
to disrupt the function of mature ribosomes in the cytosol via other agents in order to render 
tumour cells non-viable. 
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Although the research herein demonstrates the potential connection between successful 
chemotherapy treatment and alterations in ribosome content, further research needs to be 
conducted to solidify these findings. Specifically, further investigation into the specific sites of 
rRNA cleaved and the mechanism leading to RNA disruption in cancer cells following 
chemotherapeutic treatment will provide a much needed base of knowledge to this field. Also, 
determining the alteration of the entire subset of ribosomal proteins following treatment may 
provide a rationale for the observed rRNA cleavage
126
. The knowledge gained from these studies 
could then potentially explain how some chemotherapy-induced apoptotic events are 
precipitated, for example through retention or increased expression of RPL7
154
 in ribosomes (see 
section 1.5.3) 
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6.0 Appendix 
 
 
 
 
Figure 15 – Transverse Cryo-EM image of A-tRNA, P-tRNA and eIF-5A (A, P and 
E sites) bound to yeast 80S ribosome. Figure adapted from Schmidt et al (2015)
179
, 
Figure 1A. 
93 
 
 
 
 
 
  
Figure 16 - The 12-Å resolution cryo-EM density map of the 80S ribosome from 
Trypanosoma cruzi. The density map is shown in two side views of the 80S ribosome. 
The 40S subunit is in yellow and the 60S subunit in blue. Landmarks for the 40S subunit: 
h, head; bk, beak; sh, shoulder; b, body; tu, turret; landmarks for the 60S subunit: CP, 
central protuberance; H38, helix 38; SB, stalk base; pr, prong; SRL, sarcin–ricin loop; L1, 
L1 stalk. This figure was adapted from figure 1 as taken from Gao et al (2005)
180
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Figure 17 – Architecture of Eukaryotic ribosomal subunits along with bound ribosomal proteins. 
A) 40S B) 60S subunit. Proteins are labeled with eukaryotic names (red), differing yeast names in 
parentheses, and names of prokaryotic homologs (light blue). The figure was adapted from Figure 
2 of Klinge et al. (2012)
178
. 
A)  
B)  
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